Systemic and ocular fluid compounds as potential biomarkers in agerelated macular degeneration
Kersten, E., Paun, C. C., Schellevis, R. L., Hoyng, C. B., Delcourt, C., Lengyel, I., ... de Jong, E. K. (2017).
Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. Survey of
ophthalmology, 63. https://doi.org/10.1016/j.survophthal.2017.05.003
Published in:
Survey of ophthalmology
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2017 the authors.
This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License
(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:23. May. 2020
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/survophthal
Major review
Systemic and ocular fluid compounds as potential
biomarkers in age-related macular degeneration
Eveline Kersten, MSca,1, Constantin C. Paun, MSca,1,
Rosa L. Schellevis, MSca, Carel. B. Hoyng, PhDa, Cécile Delcourt, PhDb,c,
Imre Lengyel, PhDd, Tunde Peto, PhDe, Marius Ueffing, PhDf,
Caroline C.W. Klaver, PhDa,g,h, Sascha Dammeier, PhDf,
Anneke I. den Hollander, PhDa,i, Eiko K. de Jong, PhDa,*
a
Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical
Center, Nijmegen, the Netherlands
b
Université de Bordeaux, ISPED, Bordeaux, France
c
INSERM, U1219eBordeaux Population Health Research Center, Bordeaux, France
d
Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast,
Northern Ireland, United Kingdom
e
Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast, Northern
Ireland, United Kingdom
f
Department for Ophthalmology and Medical Bioanalytics Centre Tübingen, Institute for Ophthalmic Research,
University of Tübingen, Tübingen, Germany
g
Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
h
Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands
i
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
article info
abstract
Article history:
Received 29 November 2016
Biomarkers can help unravel mechanisms of disease and identify new targets for therapy.
Received in revised form 9 May 2017
They can also be useful in clinical practice for monitoring disease progression, evaluation of
Accepted 9 May 2017
treatment efficacy, and risk assessment in multifactorial diseases, such as age-related macular
Available online 15 May 2017
degeneration (AMD). AMD is a highly prevalent progressive retinal disorder for which multiple
genetic and environmental risk factors have been described, but the exact etiology is not yet
Keywords:
fully understood. Many compounds have been evaluated for their association with AMD. We
age-related macular degeneration
performed an extensive literature review of all compounds measured in serum, plasma, vit-
biomarkers
reous, aqueous humor, and urine of AMD patients. Over 3600 articles were screened, resulting
serum
in more than 100 different compounds analyzed in AMD studies, involved in neo-
plasma
vascularization, immunity, lipid metabolism, extracellular matrix, oxidative stress, diet, hor-
vitreous
mones, and comorbidities (such as kidney disease). For each compound, we provide a short
aqueous
description of its function and discuss the results of the studies in relation to its usefulness as
AMD biomarker. In addition, biomarkers identified by hypothesis-free techniques, including
* Corresponding author: Eiko K. de Jong, PhD, Department of Ophthalmology, Radboud University Medical Center, Philips van Leydenlaan 15, 6525 EX Nijmegen, the Netherlands.
E-mail address: eiko.dejong@radboudumc.nl (E.K. de Jong).
1
Eveline Kersten and Constantin C. Paun contributed equally to this work should therefore be regarded as equivalent authors.
0039-6257/ ª 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.survophthal.2017.05.003
10
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
metabolomics, proteomics, and epigenomics, are covered. In summary, compounds belonging
to the oxidative stress pathway, the complement system, and lipid metabolism are the most
promising biomarker candidates for AMD. We hope that this comprehensive survey of the
literature on systemic and ocular fluid compounds as potential biomarkers in AMD will provide
a stepping stone for future research and possible implementation in clinical practice.
ª 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1.
Introduction
The term biomarker refers to an objective, measurable
characteristic that is indicative of a biological process (normal,
pathogenic, or in response to treatment).30 Biomarkers can
help unravel mechanisms of disease and identify (new)
targets for treatment. The potential benefit of biomarkers in
drug development is to allow earlier, more robust drug safety
and efficacy measurements.385 In addition, biomarkers can be
useful in clinical practice for detecting disease, monitoring
disease progression, evaluation of treatment efficacy, and risk
assessment. Biomarker testing is an important step toward
personalized medicine in many diseases, such as cancer,198
but also in age-related macular degeneration (AMD).
AMD is the leading cause of irreversible loss of vision
among the elderly in the Western world, and the prevalence of
AMD is expected to increase with population ageing.364
The early stage of AMD is characterized by subretinal
yellowish deposits, known as drusen, and changes in macular
pigmentation.43,151 At this stage, patients usually express little
or no complaints. As AMD progresses, central vision becomes
increasingly blurred, resulting in irreversible vision loss in the
advanced stages of the disease. Two subtypes of advanced
AMD can be distinguished: geographic atrophy (GA) and
neovascular AMD (nAMD).43,151 The atrophic form of AMD is
characterized by cell death of the retinal pigment epithelium
(RPE) and photoreceptors causing gradual vision loss.136 Neovascular AMD, also referred to as “wet” or “exudative” AMD, is
characterized by abnormal vessel growth into the retina from
the choroid (choroidal neovascularization [CNV]). Leakage
from these fragile neovascularizations can cause rapid loss of
vision.363 In this review, we will use the following terms for
the different AMD subgroups described in literature: any AMD,
early AMD, advanced AMD (GA/neovascular/any advanced),
and dry AMD (for definitions of these terms, see Table 1).
AMD is a multifactorial disease, and many risk factors for
the development of AMD have been described. The most
commonly reported environmental risk factors include aging,
smoking, family history, low dietary intake of antioxidants
and omega-3 fatty acids, and reduced physical activity.44,192,204 In addition, multiple genetic risk factors have been
identified, consisting of genetic variants that are either common or rare in the population. A large risk effect has been
reported for genetic variants located at the CFH and ARMS2/
HTRA1 loci.101 Most genes associated with AMD can be clustered into 5 main pathways: the complement pathway, lipid
transport, extracellular matrix (ECM) remodeling, angiogenesis, and cell survival.100 Despite considerable progress in
understanding the genetic architecture of AMD, the exact
disease etiology is not yet fully understood.
In attempts to unravel the etiology of AMD, to improve
patient stratification, to monitor disease progression, and to
discover new drug targets, many biomarker studies have been
performed. In general, new analytical strategies have
emerged, moving from single markers toward complex
biomarker signatures, increasing the chance for greater
specificity and a higher diagnostic or predictive value.
There has been no comprehensive overview of all potential
biomarkers and their applicability in AMD. Here, we present a
detailed summary of the current literature on molecular compounds reported as analyzed in serum, plasma, aqueous humor,
vitreous, and urine of AMD patients. The scope of this review is
limited to nongenetic chemical compounds. For all compounds,
a short description of their function is provided, and the results
of the studies are summarized and discussed in relation to AMD.
Currently, most of these markers are not yet established as
routine clinical diagnostic tools and are discussed here to direct
future research and eventually clinical implementation.
2.
Neovascularization and hemostasis
Because choroidal neovascularization is one of the subtypes of
advanced AMD, it is not surprising that the factors involved in
neovascularization and hemostasis have been extensively
studied. The results of the studies describing these factors are
described in Sections 2.1 and 2.2, respectively. A complete
overview of the studies and references is provided in Supplementary Table 1.
2.1.
Neovascularization
2.1.1. Vascular endothelial growth factor and soluble VEGF
receptor 1
Vascular endothelial growth factor (VEGF) is currently the
most important target in the treatment of nAMD, and the
expression profile of VEGF has been extensively investigated
in AMD patients. VEGF acts as a hypoxia-driven local signal to
induce the formation of new blood vessels. Treatments
inhibiting its function can partially restore and/or maintain
vision in nAMD patients.
Contrary to expectation, VEGF is not consistently upregulated in AMD patients across studies. One study showed that
VEGF levels in the aqueous humor of 12 nAMD patients were
highly elevated (668.9 pg/mL) compared with 10 controls
(cataract patients; 108.3 pg/mL).334 In a second study involving
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
11
Table 1 e Explanation of terms used in this review to describe different types of AMD
Type of AMD
Any AMD
Early AMD
Advanced: GA
Advanced: neovascular
Any advanced AMD
Dry AMD
Criteria
No specific definition of AMD reported or analyses were performed on all AMD stages together
Analyses were performed on AMD cases in the absence of advanced stage disease (GA or CNV) and
can include early and/or intermediate AMD
Geographic atrophy of the RPE secondary to AMD
Choroidal neovascular lesion (active or occult) secondary to AMD, including serous and/or hemorrhagic
RPE detachment, subretinal fibrovascular tissue and scarring
No specific definition of advanced AMD reported or analyses were performed on both advanced AMD
stages (GA and CNV) together
No specific definition of dry AMD reported or analyses were performed on AMD cases in the absence of
advanced neovascular AMD (can therefore include early AMD and/or advanced: GA)
AMD, age-related macular degeneration; CNV, choroidal neovascularization; GA, geographic atrophy; RPE, retinal pigment epithelium.
aqueous humor, however, significant higher VEGF levels could
only be demonstrated in the most aggressive form of nAMD
(type 3 neovascularization) compared with controls.74 A third
study did not report a difference in VEGF levels in aqueous
humor between nAMD and controls at all.290 Of note, a
considerable range in VEGF levels in aqueous humor exists
among these studies. In the study by Tong and colleagues,334
the levels of VEGF in control individuals were around 100 pg/
mL, whereas the VEGF levels in the 2 other studies were much
lower in controls (39.5 pg/mL and 63.9 pg/mL, respectively).74,290 These differences may be explained by the use of 3
different analytical systems, emphasizing the need for standardized assay systems for key marker compounds in eye
fluids. In addition, studies analyzing VEGF levels in vitreous
samples did not detect differences between VEGF levels of
nAMD cases and controls.135,142
Although the measurement of VEGF levels in vitreous or
aqueous humor is expected to best reflect VEGF levels in the
macula, the procedure is invasive and therefore not desirable in
individuals with early or intermediate AMD. Thus, for purposes
of a clinical tool for diagnosis and progression, measurement of
VEGF levels in more accessible body fluids such as serum or
plasma is preferable. Several studies did investigate VEGF levels
in AMD patients and controls in serum or plasma, with mixed
results. Four studies detected significantly upregulated levels of
VEGF in serum or plasma,6,115,205,338 but these findings are
contrasted with 10 other studies that reported no
association.41,80,112,122,125,211,231,299,353,380
VEGF signaling is mediated through a complex of receptors
and coreceptors, of which the soluble form of VEGF receptor 1
has been investigated in a number of studies. As in the case of
VEGF, these studies do not offer a clear direction of effect. One
study investigated the levels of soluble form of VEGF receptor
in vitreous and found that levels were higher in nAMD
patients.142 In contrast, 2 studies performed on serum could
not corroborate these findings. One of the studies did not find
any association,256 the other even reported lower levels of
soluble form of VEGF receptor in nAMD.340
2.1.2.
Pigment epitheliumederived factor
Pigment epitheliumederived factor (PEDF) is produced by RPE
cells and has antiangiogenic properties, opposing the effects
of VEGF. It has been proposed as a target to inhibit choroidal
neovascularization and its expression signature in model
systems suggests that it is downregulated under hypoxic
conditions.139 Two studies on vitreous support this by
demonstrating a marked reduction in PEDF levels in AMD
patients versus controls.135,142 One study analyzing aqueous
humor showed the opposite result, an increase of PEDF levels
in AMD patients.334 These conflicting results are not readily
explained. It is possible that in different fluids or in different
parts of the eye (anterior/posterior), PEDF is regulated differently, but additional experiments are needed to determine the
direction of the effect with certainty.
2.1.3.
Transforming growth factor beta
Transforming growth factor beta (TGF-b) has been described to
increase the expression of VEGF and is therefore also implicated in neovascularization.20 In vitreous samples of nAMD
patients, TGF-b was significantly elevated when compared with
controls (patients with idiopathic macular holes).20 An earlier
study had already demonstrated that urinary TGF-b levels were
increased in cases compared with controls, but only in early
AMD was the difference significant.121
2.2.
Hemostatic system
2.2.1.
Fibrinogen
Fibrinogen is a hemorheological factor involved in endothelial
functioning.34 Abnormalities in this factor are linked to
thrombogenesis and vascular disorders166; hence, fibrinogen
has been examined for its potential involvement in AMD.
Studies have yielded mixed results. A number showed that
increased fibrinogen level is a significant risk factor,65,205,223,271,321 whereas others did not find evidence for an
association.58,149,185,188,288,295,331,352,367
2.2.2.
Plasminogen activator inhibitor 1
Plasminogen activator inhibitor 1 is another main component of
the fibrinolytic system.29 Four studies have investigated whether
a relation between plasminogen activator inhibitor 1 and AMD
exists, with some support for a positive association,367 whereas
other studies did not find any association.26,288,352
2.2.3.
Platelet count
Several studies have measured platelet count. Most did not find
any association between platelet counts and AMD.149,180,181,186,205
12
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Two larger studies did find lower platelet counts in AMD, but this
minimally protective effect for platelets on the development of
AMD was only significant in univariate analyses.50,285
2.2.4.
3.
The human body is dependent on an aerobic environment for
survival. This constant exposure to oxygen can lead to detrimental oxidative modifications of cell components and tissues. Usually, cells are equipped with sufficient antioxidative
mechanisms to maintain oxidant homeostasis, but if this
balance is disrupted, oxidative stress occurs.38 Oxidative
stress in cells and tissues is characterized by an excess in
molecules containing free radicals such as reactive oxygen
species (ROS) and reactive nitrogen species.
Polyunsaturated fatty acid (PUFA) molecules are present in
lipids on the membranes of cells and are prone to oxidation
due to the presence of susceptible double carbon bonds.38,245
During the process of lipid peroxidation by ROS, the double
carbon bond is oxidized, leading to the formation of unstable
Von Willebrand factor
Von Willebrand factor is a blood glycoprotein that is essential
for normal hemostasis.289 Because vascular pathology is hypothesized to be involved in the pathogenesis of AMD, Von
Willebrand factor was investigated as a possible risk factor. One
study showed higher levels compared with controls (but in
multivariate analysis no significant correlation was found),205
and 3 more studies found no association at all.288,352,367
In summary, many inconsistent results for factors involved
in neovascularization have been reported, and further work is
required to determine whether these could be used as AMD
biomarkers. Factors involved in hemostasis described in Section 2.2 are unlikely to serve as biomarkers for AMD.
Loss of function
Oxidative stress
SOD
O
Carbonyl
Protein
hyd
roly
Vit C
Ox
Vit E
sis
ONOO
Vit C
Ox
Vit B6
Oxidation
Apoptosis
a uto-oxidation
Vit E
Vit B9 Vit B12
Homocystine
Lipids
ApoA1
HCTL
Binding
g
di
n
Bi
n
LDL
Loss of function
HCTL
ke
MDA
HCTL
Protein
ApoB100
ta
Up
ing
Protein
LDL
Bind
CEP
n
Ox
MDA
tio
yla
in
te
ys
oc
m
Ho
PON1
Protein
CD
36
Foam cell
Downregulated
CFH
Upregulated
_
Angiogenesis
Inflammation
Up/Downregulated
Fig. 1 e Networks of oxidative stress in age related macular degeneration (AMD). Spheres are colored to indicate levels in AMD
patients compared to controls based on literature: upregulated (green), downregulated (blue), or inconsistent levels (gray). In
this figure, studies reporting no association were not taken into account for the sake of readability. Apo, apolipoprotein; CEP,
2-(u-carboxyethyl) carboxyethylpyrrole; DHA, docosahexaenoic acid; GSH, glutathione; GSHP, glutathione peroxidase; GSHR,
glutathione reductase; HCTL, homocysteine thiolactone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDA,
malondialdehyde; MS, methionine synthase; Ox, oxidized; PON1, paraoxonase 1; PUFA, polyunsaturated fatty acid; RNS,
reactive nitrogen species; ROS, reactive oxygen species; SOD, superoxide dismutase; Vit, vitamin.
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
reactive carbonyl compounds (e.g., malondialdehyde
[MDA]).18,22,263,357 ROS can also oxidize proteins, resulting in 2(u-carboxyethyl) pyrrole (CEP) protein adducts117 and induce
formation of advanced glycosylation end products (e.g.,
Nε-carboxymethyllysine).146,304
Increased oxidative stress is thought to be one of the underlying factors in the occurrence of AMD.18,24,38,245,333,374 The
eye, and especially the macula, is susceptible to oxidative
stress because of its high metabolic activity and high PUFA
content in the membranes of the photoreceptors.38 High oxygen pressure from the blood in the choroid and exposure to
bright light also causes increased ROS levels in the
retina.22,263,333 In addition, photoreceptors are subjected to
constant shedding, and subsequent phagocytosis of the shed
fragments leads to ROS generation.38,374 Environmental
factors such as smoking and alcohol consumption can also
increase ROS production.346 Therefore, factors related to
oxidative stress could potentially be valuable biomarkers for
the incidence and/or progression of AMD and are discussed in
more detail in Sections 3.1e3.4. A schematic overview of these
oxidative stress related factors is provided in Fig. 1 and a
complete overview of the studies and references is provided in
Supplementary Table 2.
CML is an advanced glycation end product that originates
from a protein lysine modification and is a major immunological epitope recognized by the immune system.146 Plasma
CML levels were upregulated in AMD in one study,242 but no
significant difference was found in another.304
Both CEP adducts and CML are present on proteins. They
are recognized by the immune system146,359 and can stimulate
angiogenesis in vivo.78,248 Receptor-mediated binding of CEP
adducts results in an angiogenic response of endothelial cells
independent of VEGF signaling.359 Upregulation of CML and
CEP levels in AMD might be implicated in the progression toward nAMD by promoting angiogenesis, but further studies
are necessary to support this hypothesis.
3.1.3.
Oxidation products
3.1.1.
Malondialdehyde
MDA is one of the reactive carbonyl compounds originating from
PUFA oxidation, and its presence is often used to measure lipid
peroxidation levels in blood or serum samples.18,22,335 Increased
systemic levels of MDA have been consistently observed in both
wet and dry AMD.18,22,86,155,263,311,335,336,346,374,375 In addition, an
allele-dependent increase of MDA levels was measured in
subjects carrying the A69S variant (rs10490924) in the ARMS2
gene that is associated with AMD. Patients heterozygous or
homozygous for the risk allele showed higher MDA levels.263
MDA is a highly reactive molecule that forms covalent bonds
with the amino acids of endogenous proteins. This MDA modification can be recognized by factors of the innate immune
system such as complement factor H (FH), immunoglobulin M
(IgM), and macrophages.53,357,358 Binding of MDA by IgM or
macrophages leads to a proinflammatory response by
increasing the expression of the inflammation factor interleukin
(IL)-8,274,358 whereas binding to FH attenuates inflammation.358
3.1.2.
CEP adducts and N(6)-carboxymethyllysine (CML)
Docosahexaenoic acid (DHA) accounts for about 80% of all
PUFAs in the photoreceptor outer segments and is most prone
to oxidation in human tissues.96 Upon oxidative stress, DHA is
oxidized forming specific CEP adducts.117 Plasma CEP levels in
AMD patients are elevated compared with controls.118,242,351
Moreover, elevated CEP levels combined with AMD risk
alleles in ARMS2, HTRA1, CFH, or C3 increased the risk of AMD
twofold to threefold compared with genotype alone.118
Furthermore, plasma of AMD patients contained more and
a higher diversity of CEP autoantibodies compared with
controls in 2 studies from the same group.117,118 Another
independent study found no association between CEP autoantibodies and AMD.242
Protein carbonyl groups and total oxidation status
Levels of protein carbonyl groups are often used to assess the
total protein oxidation status in subjects as they are easy to
measure.64 Protein carbonyl groups consist of an oxygen
molecule bound to a carbon atom with a double bond (-RC¼O)
resulting from protein oxidation and are therefore indicative
of oxidative stress. Elevated levels of both protein carbonyl
group336,379 and total oxidation status336,341 were found in
nAMD patients.
3.1.4.
3.1.
13
Oxidized low density lipoprotein
Low-density lipoprotein (LDL) is abundantly present in and
around cells and is an easy target for oxidation by ROS. LDL
cholesterol (LDL-C) has been studied extensively in the
context of AMD, described in Section 5.2; however, studies on
its oxidized form (oxidized low density lipoprotein [Ox-LDL])
are more limited. Higher Ox-LDL levels were found systemically in AMD patients compared with controls,147,152,153 but a
lack of association has also been reported.184
Increased Ox-LDL levels are known to activate various
factors of the complement system such as C3b, C5b-9, and
complement factor B (FB).79 These factors are described in more
detail in Section 4.1. High Ox-LDL levels as observed in AMD
might initiate apoptosis of RPE cells through disruption of the
mitochondrial pro- (Bax) and antiapoptotic (Bcl2) balance,373
leading to GA. In addition, uptake of Ox-LDL molecules by
macrophages contributes to the formation of foam cells,
implicated in the development of atherosclerotic plaques.270
3.2.
Nitric oxide
Nitric oxide is one of the most abundant free radicals in the
human body and is able to react with other ROS resulting in
cell dysfunction and apoptosis.86 It is synthesized by endothelial cells and is an important vasoactive agent affecting
blood flow and other vascular functions.28 Involvement of
nitric oxide in AMD is less clear. One study observed increased
levels of nitric oxide in AMD patients,86 another study
described downregulation of nitric oxide in nAMD,335 and a
third study reported no association.338
3.3.
Homocysteine
Homocysteine is an intermediate molecule in the conversion of
the amino acid methionine to cysteine and glutathione (GSH), a
process mediated by multiple enzymes.104,294 Homocysteine
14
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
can autooxidize in plasma, leading to the formation of various
reactive products such as homocysteine thiolactone, which is
also accompanied by ROS generation (Fig. 1).60
Dysregulation of the homocysteine balance has been
associated with various diseases such as vascular dysfunction, autoimmune diseases, and neurodegenerative disorders.294 Increased systemic levels of homocysteine were
observed in both neovascular and dry forms of AMD compared
with controls,18,19,60,110,113,152,153,168,213,284,300,347 and there
were also higher levels in the vitreous of nAMD patients.213
Moreover, some studies found higher homocysteine levels in
nAMD compared with dry AMD19,110; however, other studies
did not find an association between homocysteine levels and
AMD.54,132,188,247,352,367
3.4.
Antioxidants
Antioxidants enhance ROS clearance and prevent ROS formation thereby averting damage in the aging eye and other
tissues.333 Enzymes such as catalase, superoxide dismutase,
and paraoxonase prevent the accumulation of oxidized lipids
by converting ROS before they can react or by removing the
oxidized products from the endogenous proteins.333 Several
vitamins and trace elements act as cofactors for these
enzymes, or react with ROS to prevent accumulation.357,374
Multiple studies hypothesized that the antioxidant capacity
in AMD patients might be impaired, and some showed a
decreased overall antioxidant capacity in serum of patients.58,87,269,311,336,379 In the following sections, we discuss levels
of thiols (Section 3.4.1), carotenoids (Section 3.4.2), and enzymes
with antioxidant activity (Section 3.4.3) in AMD patients.
3.4.1.
Thiols and GSH
Thiols mediate an important part of the balance between
proper oxidation versus antioxidants in tissues. Their main
characteristic is a carbon-bonded sulfhydryl group (C-SH),
which can form a disulfide bridge with other thiols via redox
reactions (C-S-S-C). Thiols can neutralize ROS by providing an
electron during the formation of the disulfide bridge.218
Although their normal function is to prevent oxidative
stress, thiols can also promote oxidative stress in the presence
of metal ions such as iron.152
Thiol content is either measured by focusing on the individual thiols or by evaluating total thiol (tSH) content of the
blood. GSH is one of the most important thiols in the body.
GSH can be transformed into glutathione disulfide (GS-SG) by
the enzyme glutathione peroxidase (GSHP), thereby breaking
down hydrogen peroxide (2 GSH þ H2O2 / GS-SG þ 2 H2O).218
Glutathione reductase (GSHR) is able to transform the formed
glutathione disulfide to its monomeric form (GS-SG þ NADPH
þ Hþ / 2 GSH þ NADPþ), making it available for conversion by
GSHP again.218 This circular process (Fig. 1) is of vital importance for proper ROS maintenance.
Lower levels of GSH and tSH are thought to result in more
ROS formation owing to the absence of hydrogen peroxide
clearance, resulting in subsequent oxidative damage.60,333 Lower
levels of total thiol content60,152,341 and plasma GSH60,152 were
found in patients with AMD compared with control subjects,
and both were negatively correlated with homocysteine levels60;
however, multiple studies have found no association between
systemic GSH levels and AMD.35,72,273,291,375
Plasma and serum GSHR levels were lowered in patients
with AMD,55,58,379 although 1 study did not find this association in erythrocytes.68 Systemic GSHP levels were lowered in
some studies85,269,272,346 and higher in 1 study,71 but in most
studies, no association was found.55,58,68,375,379
3.4.2.
Carotenoids
Carotenoids are a group of natural red and yellow hued pigments (carotenes and xanthophylls) synthesized in most
plants. The antioxidant capacity of carotenoids is based on
their ability to absorb and process free electrons from ROS
such as singlet oxygen (1O2) and peroxyl radicals (ROO). After
the uptake of an electron, the carotenoid releases its energy in
the form of heat and can be used again. Humans are unable to
synthesize carotenoids and rely on dietary intake of vegetables.95,325 In AMD, total serum carotenoid levels were
decreased in 2 studies by the same group,87,88 whereas 2 other
studies described a lack of association.40,313
Two main xanthophylls are located in the macula: lutein is
concentrated in the peripheral macula and zeaxanthin in the
fovea. Here, they are able to attenuate blue light wavelengths,
preventing the light from reaching and damaging the underlying photoreceptors.195 In blood, lutein and zeaxanthin are
transported by lipoproteins such as high-density lipopotein
(HDL) and LDL. Zeaxanthin and lutein exert their antioxidant
abilities by reacting with free radicals both in the macula and
in blood.195 Levels of lutein and zeaxanthin were found to be
decreased in AMD patients in several studies.70,87,384 One
study described decreased levels of zeaxanthin but not lutein
in AMD patients.103 Others found no association for either
lutein or zeaxanthin.40,214,224,292,313
b-cryptoxanthin is a carotenoid most commonly found in
citrus fruits. Besides its role as an antioxidant, in vitro experiments have shown that b-cryptoxanthin also stimulates
DNA repair mechanisms.206 Levels of b-cryptoxanthin were
decreased in patients with advanced AMD in some
studies,87,224,313,384 whereas others did not find a significant
association with AMD.40,70,214,292
A decrease of a-carotene was found in patients with
nAMD,87,384 whereas higher levels of a-carotene were present
in early AMD.384 Also b-carotene levels were decreased in
advanced AMD in some studies87,224,384; however, most
studies did not find a significant association between AMD
and a-carotene or b-carotene levels.40,70,214,224,292,313,322,360
Importantly, supplementation of b-carotene has been associated with an increased risk of lung cancer in smokers and
former smokers, and therefore, long-term use to inhibit AMD
progression is not recommended.5,251
Finally, one of the most potent antioxidants present in
blood is lycopene. The main dietary sources of this red
pigment carotenoid are red fruits or vegetables, such as tomatoes.102 Levels of lycopene were either decreased in AMD
patients40,313,384 or not associated with AMD.70,87,214,224,292
In summary, when studies reported a significant association between carotenoids and AMD, the vast majority
described decreased carotenoid levels in patients. This probably reflects a difference in dietary intake of these carotenoids
between AMD patients and controls. Several studies reported
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
that a higher intake of carotenoids is associated with a
reduced risk of AMD.332,344,365 In addition, a beneficial effect
was shown for supplementation with lutein and zeaxanthin
on progression to advanced AMD.3e5
3.4.3. Enzymes
3.4.3.1. Superoxide dismutase. Superoxide dismutase (SOD) is
an important antioxidant that catalyzes the conversion of superoxide (O2 ) into oxygen and hydrogen peroxide (H2O2).333
Two families of SOD exist based on their metal ion cofactor:
SOD1 (CuZnSOD), which is localized to the cytoplasm and SOD2
(MnSOD), found in mitochondria.333 The absence of SOD1 or
SOD2 has been associated with early retinal cell degeneration
in mice,129,164 suggesting an important role for SOD in the eye.
With regard to AMD, several reports show elevated
systemic SOD activity in AMD patients compared with
controls,10,155,310,311 others found lowered SOD activity
levels,86,272,346,375,379 and still others measured no significant
association.55,58,68,71,269 One study showed a significant
difference in SOD activity between late and early AMD, with a
lower SOD activity in late AMD patients.86
The association of both low and high SOD serum activity
levels with AMD might be explained by the damaging effects
of both high and low levels of SOD. High levels of SOD lead to
higher H2O2 production, whereas low SOD activity leads to the
continuing presence of O2 molecules. The detrimental effects
of both low SOD and high SOD activity on ROS production
suggest that imbalance of the enzyme activity leads to pathological conditions and that proper SOD balance is important
to maintain homeostasis.
3.4.3.2. Paraoxonase 1. Paraoxonase 1 (PON1) is bound to HDL.
PON1 hydrolyzes organophosphates and lipid peroxides and
inhibits the oxidation of LDL.18,153 In addition, PON1 is able to
detoxify homocysteine thiolactone, one of the highly reactive
metabolites of homocysteine.151 Active PON1 interacts with
oxidized proteins or lipids, leading to its own inactivation.17
The low serum PON1 activity levels observed in AMD patients18,22,341 could be due to inactivation of PON1 after
reacting with oxidized proteins.
3.4.3.3. Catalase. Catalases are important in ROS clearance by
converting hydrogen peroxide (H2O2) to oxygen and water.47 In
AMD, 3 studies reported downregulated systemic catalase
activity levels,272,346,374 whereas 3 others reported no difference in catalase activity levels between AMD patients and
controls.68,86,269
Taken together, dysregulation of the oxidative stress
pathway and the manner in which oxidative stress is
managed by the body seems to play an important role in AMD.
A large number of investigators have reported decreased
levels of antioxidants and elevated oxidized protein or lipid
levels (Fig. 1). The most promising biomarker candidates in
the oxidative stress pathway are MDA and homocysteine,
which were consistently reported to be increased in AMD
patients. For other factors, however, the reported associations
were less clear and with mixed results. This could indicate
that an imbalance of the entire oxidative stress system may
play a role, rather than levels of individual factors of this
system specifically.
4.
15
Immunity
The involvement of the immune system in the pathology of
AMD is widely accepted, and some suggest reframing AMD as
an autoimmune disease.39 The activity of the immune system
in AMD, both innate and adaptive, has been implicated at
several levels. Immune cell infiltrates have been shown in the
retinas of AMD patients examined postmortem,198 with
evidence of cytokine/chemokine expression at the affected
site, as described in more detail in Section 4.2.
Strong evidence for the involvement of the immune system in AMD also comes from several GWAS studies (described
in Section 1).99,101 In particular, the role of the complement
system is apparent. In the following sections, we discuss
immunity-related compounds, including systemic markers of
the complement system (Section 4.1) and elements of adaptive and innate immunity (Sections 4.2e4.4). A complete
overview of the studies and references is provided in Supplementary Table 3.
4.1.
The complement system
The complement system is an integral part of innate
immunity with essential roles in protection against foreign
intruders via tissue inflammation, cell opsonization, and
cytolysis. It is also involved in monitoring and maintaining
host tissues by clearing cellular debris, maintaining cellular
integrity, tissue homeostasis, and modifying the adaptive
immune responses.105
Ever since histopathological studies demonstrated the
presence of complement components in drusen,11,127 the
involvement of the complement system in AMD has been
studied extensively and genetic evidence showing strong links
between components of the alternative pathway of the
complement system and AMD followed.101,193 Although the
complement system acts locally, its components can also be
detected systemically in serum or plasma. A number of studies
have investigated the expression levels of complement
regulators, complement components, and activation products
in AMD patients versus controls. An overview of the alternative
pathway of the complement system is provided in Fig. 2.
The central molecule of the complement system is
complement component 3 (C3). Enzymatic cleavage of C3
results in the generation of its active fragments C3a (a potent
proinflammatory molecule) and C3b that, via several digestion
steps, leads to C3d.220 A number of studies measured systemic
C3 levels but did not find an association with AMD,278,298,312,319
whereas higher systemic levels of its active fragments, C3a
and C3d, were detected in AMD patients.130,278,298,319 These
findings suggest that the processing of C3, that is its activation, may be associated with AMD and a number of studies
have investigated this. Complement activation was measured
as the ratio of C3 and its degradation product C3d (C3d/
C3)280,281,319 or as a cleaved form of C3a (C3a-desArg) in
blood317 and urine.121 Of the 5 studies that investigated
complement activation in AMD, 4 found higher complement
activation levels in AMD patients.280,281,317,319 An association
of C3a-desArg in urine with AMD was not established.121 A
recent study suggests that complement activation levels may
16
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
C3d
2.
C3c
Ba
3.
C3b
C3b
C3b
B
FB
Bb
FD
FD
Cofactor
1.
C3
FI**
C3a
+
Upregulated
FH*
Upregulated/No difference
Up/Downregulated
4.
C3b
No difference
C3b
5.
C3b
Bb
Bb
C3b
C3-convertase
C5-convertase
DAF*
+
C5a
C5
C6
C5b
C7
C8
C9
SC5b-9
6.
Fig. 2 e Overview of the alternative pathway of the complement system. Spheres are colored to indicate levels in AMD
patients compared with controls based on literature: upregulated (green), upregulated/no difference (dark green),
upregulated/downregulated (gray), and no difference (yellow). (1) Complement component 3 (C3) splits into C3a and C3b by
spontaneous hydrolyzation or by the C3-convertase (C4bC2) resulting from activation of the classical or lection pathway. (2)
Factor B (FB) can bind C3b to form C3bB. (3) The bound factor B is then cleaved by factor D (FD) which results in the formation
of the C3-convertase: C3bBb (4). This C3-convertase can cleave C3 which leads to more C3b and in turn increased formation
of the C3-convertase (known as the C3 amplification loop). The C3-convertase can also bind another C3b molecule to form
C3bBb3b, which is a C5-convertase (5). This C5-convertase can convert C5 into C5a and C5b. (6) C5b then sequentially binds
C6, C7, C8, and multiple C9 molecules to form the terminal complement complex (SC5b-9), also known as membrane attack
complex. * The C3-convertase is inhibited by several complement regulators, among which decay accelerating factor (DAF)
and factor H (FH). ** Factor I (FI) can breakdown C3b via several digestion steps to C3c and finally C3d, this protease activity,
however, requires a cofactor, such as FH.
decrease at more advanced stages of the disease, but this
finding needs to be confirmed in prospective AMD cohorts.320
Besides C3, complement component 5 (C5) is also essential
in the activation cascade because it serves as the entry point
for the formation of the terminal complement complex
(SC5b-9).220 The activation product of C5, C5a, is a potent
anaphylatoxin. Increased levels of C5a were detected in most,
but not all130 studies examining the role of C5a in
AMD.278,298,319 These same studies also tested whether SC5b-9
is associated with AMD. Higher SC5b-9 levels were detected in
AMD in 1 study,298 but the other 2 studies found no evidence
for an association.278,319
The activity of the complement system is tightly controlled
by regulatory factors that ensure appropriate, but not excessive,
generation of terminal complexes. Among others, they include
complement FH (encoded by the CFH gene), factor I (FI, encoded
by CFI ), FB (encoded by CFB), factor D (FD, encoded by CFD), and
decay accelerating factor (DAF/CD55, encoded by CD55).220
Genetic association studies showed strong evidence of an
association between the CFH gene and AMD.101 Systemic
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
levels of FH have been investigated with mixed results, however. Four studies report lower FH levels in AMD,14,278,308,310 1
study detected higher levels of FH in AMD,128 and another 4
studies did not find an association with AMD.120,298,312,319
Similar to FH, FI also inhibits the activity of the complement system through inactivation of C3b. Genetic evidence for FI involvement in AMD has been shown
previously, but no conclusive evidence links FI levels to
AMD in general. One study reports increased FI levels in
AMD,312 another reports decreased levels but only in patients carrying a rare genetic variant in CFI,343 and 2 did not
find any association.278,319
The findings for FB and FD levels in AMD are also inconsistent. Three studies reported higher FB levels in AMD patients,130,298,319 whereas 2 others did not detect an association
with AMD.278,312 Similar results were described for FD, where 3
studies reported higher FD levels,130,298,326 1 study reported
lower levels in AMD,312 and another found no association with
AMD.278 Finally, 2 studies that examined the role of CD55 did
not find evidence for an association with AMD.123,314
In summary, not only genetic studies but also studies
measuring complement components provide evidence that
link complement activation to AMD (Table 2). Some factors,
however, should be taken into account when considering the
use of systemic complement activation levels as a biomarker
for AMD in individual patients. Often antibody-based tests do
not discriminate between the total amount of a specific
complement factor and its processed activated part, as
cleavage of the proform to the active mature form cannot be
distinguished by the reagent. Moreover, complement activation levels are subject to high variability, and other causes of
increased complement activity should be excluded because
increased complement activation may reflect immune system
activity that is not necessarily connected to disease progression. Linking exacerbated complement activation in an individual patient to his or her genetic blueprint is potentially
more useful. For example, haplotypes and combinations of
genotypes in several complement genes have been associated
with increased complement activation levels.1308,266 In
addition, several investigations have now demonstrated that
FI levels are lower in AMD patients carrying rare genetic variants in the CFI gene.107,172,343 For FH levels, there were similar
associations with genotype. Some but not all rare variants in
the CFH gene were associated with reduced FH levels.337,349,378
Thus, patients carrying rare variants in complement genes
tend to have higher complement activation levels than
AMD patients in general.106 These insights may benefit
ongoing clinical trials on the effectiveness of complement
inhibitors and could prioritize patients who carry rare variants
in these genes.
4.2.
Cytokines
4.2.1.
Interleukins
Cytokines are a large family of small proteins that play a
pivotal role in cell signaling. An important group of cytokines
are interleukins. Interleukins play a key signaling role in the
inflammatory response. Interleukin-6 (IL-6) is a cytokine with
many described functions,215,225 and its relationship to AMD
has been investigated. A number of studies reported increased
17
levels of IL-6 in AMD patients,7,124,191 but the majority found
no association with AMD in general.15,58,183,188,231,240,290,352,367
Notably, a number of these studies did find an association in
subgroup analyses. For instance, an association with AMD
was reported only in patients with high IL-6 levels58 or the
association with IL-6 was established only for GA patients.188
In addition, only the highest tertile of IL-6 levels was associated with progression of AMD in a prospective cohort study.303
Other interleukins have also been studied in relation to
AMD, although to a lesser extent. In most studies, these interleukins were measured in a multiplex analysis of inflammatory markers. Two studies measured multiple interleukins
in serum.231,240 In 1 study, there were higher serum levels of IL1b, IL-4, IL-5, IL-10, and IL-13 in patients with nAMD,240 but
these factors were not associated with early, atrophic, or neovascular AMD in another study.231 Higher serum levels of IL-1a
and IL-17 in nAMD patients were only reported in the first
study. In addition, no association was found for IL-2, IL-12, and
IL-15.240 Other studies also detected no association between IL2,188 IL-15,89 and AMD. For IL-8, although no association was
present in 2 studies,229,235 a third larger study described higher
IL-8 levels in AMD patients, in particular in dry AMD.7 Higher
IL-18 levels were reported in dry, but not nAMD, in 1 study.143
A second study did not find different levels between different
types of AMD and controls.89
Although most studies focused on systemic levels of
interleukins, a small number performed measurements in
aqueous humor290 and vitreous.383 Higher IL-1b levels were
found in the vitreous of nAMD patients.383 In aqueous humor,
IL-1a and IL-15 were upregulated and IL-13 was downregulated, whereas for IL-2, IL-4, IL-8, IL-10, IL-12, and IL-17, no
differences were detected.290
4.2.2.
Chemokines and chemokine receptors
Chemokines (chemotactic cytokines) have the ability to direct
movement of cells through receptor-mediated chemotaxis.
Evidence from postmortem material and animal models have
implicated infiltrating immune cells in pathological eye tissues, suggestive of the involvement of chemokines in these
environments.200,287,305,329
Chemokine ligand 2 (CCL2; or monocyte chemoattractant
protein 1) attracts C-C chemokine receptor type 2 (CCR2)expressing monocytes into tissues and is one of the most
studied chemokines in AMD. Five relatively small, case-control
studies did not find an association between levels of CCL2 and
AMD,90,116,120,231,290 but several larger studies did see an association with increased levels of CCL2.9,310,382 This effect was
also reported in a cross-sectional study linking higher levels of
urinary CCL2 to early AMD.121 Overall, these findings support
the notion that CCL2 is involved in AMD. Interestingly, CCR2expressing cells can also be detected systemically, and both
decreased and increased levels have been associated with
AMD.9,115 Two other studies did not find any association.94,376
Another receptor involved in the recruitment of monocytes,
CX3C receptor 1, was measured in two AMD studies.92,116 Only
the more recent study reported CX3C receptor 1 to be upregulated in both early and neovascular AMD.92
Eotaxin (eosinophil chemotactic protein/CCL11) and
closely related eotaxin-2 (CCL24) attract eosinophils. These
are interesting molecules for AMD pathogenesis because
18
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Table 2 e Overview of studies measuring complement components in AMD patients compared with controls
Component
Upregulation
SC5b-9
Scholl et al, 2008298
Reynolds et al, 2009278
Scholl et al, 2008298
Hecker et al, 2010128
Smailhodzic et al, 2012319
Sivaprasad et al, 2007317
Smailhodzic et al, 2012319
Ristau et al, 2014280
Ristau et al, 2014281
Scholl et al, 2008298
Reynolds et al, 2009278
Smailhodzic et al, 2012319
Scholl et al, 2008298
FH
Hakobyan et al, 2008128
FI
Silva et al, 2012312
FB
Scholl et al, 2008298
Hecker et al, 2010130
Smailhodzic et al, 2012319
Scholl et al, 2008298
Hecker et al, 2010130
Stanton et al, 2011326
C3d
C3a des Arg
C3d/C3
C5a
FD
DAF/CD55
a
Downregulation
Scholl et al, 2008298
Reynolds et al, 2009278
Silva et al, 2012312
Smailhodzic et al, 2012319
C3
C3a
No difference
Guymer et al, 2011121
Hecker et al, 2010130
Reynolds et al, 2009278
Smailhodzic et al, 2012319
Scholl et al, 2008298
Silva et al, 2012312
Smailhodzic et al, 2012319
Guymer et al, 2015120
Reynolds et al, 2009278
Smailhodzic et al, 2012319
Van de Ven et al, 2013a,343
Reynolds et al, 2009278
Silva et al, 2012312
Reynolds et al, 2009278
Reynolds et al, 2009278
Ansari et al, 201314
Sharma et al, 2013308
Sharma et al, 2013310
Silva and colleagues 2012312
Haas et al, 2011123
Singh et al, 2012314
Significant downregulation of FI was described in a subgroup of patients with a rare variant in the CFI gene.
CCL11 and CCL24 and their receptor CCR3 are implicated in
choroidal neovascularization.91,309 CCR3 is expressed on
choroidal neovascular endothelial cells and signaling through
this receptor leads to endothelial proliferation, even without
the involvement of eosinophils or other immune cells.
Blocking CCR3 signaling in animals led to a potent inhibition
of neovascularization, even stronger than blocking VEGFA
signaling.329 Levels of CCL11 were investigated in 2 studies,
one reporting increased levels in AMD,231 and the other
finding no differences.91 Supportive of the aforementioned
findings, 2 studies of the same group reported CCL24 to be
upregulated in AMD.309,310 Despite these overall promising
results, systemic elevations of CCR3 on immune cells have not
yet been reported. The only study investigating CCR3 on
granulocytes reported no association, although there was a
trend toward higher expression of CCR3 in nAMD.91 Taken
together, the CCL11/CCL24-CCR3 axis is potentially involved
in human AMD pathology, but it is not yet clear whether this is
mostly a local signaling, mediated through CCR3 expression
on endothelial cells, or whether systemic CCR3-expressing
cells could also be involved.
The chemokine ligand CXCL10, also known as interferon
gamma-induced protein 10, attracts a range of cell types and is
an inhibitor of angiogenesis.13 Two studies showed no
association with CXCL10 in serum or plasma and AMD,93,116
and only 1 study showed elevated serum CXCL10 levels in
AMD patients.231 Of interest is a recent publication, showing
upregulation of CXCL10 in aqueous humor of AMD patients
compared with controls undergoing cataract surgery,290 suggesting that the effect of this chemokine might be local.
The receptor for CXCL10 is CXCR3 which is expressed on a
variety of cell types. Only one study investigated numbers of
CXCR3-expressing cells peripherally and detected reduced
presence of CD8þ T-cells expressing CXCR3 in AMD,93 but
additional research is warranted before concluding whether
the CXCL10-CXCR3 axis can be reliably used as a biomarker
for AMD.
It has been suggested that stem cell progenitor cells are
involved in the disease etiology of AMD. Chemokine ligand
CXCL12, also known as stromal cell-derived factor 1, plays a
role in the movement of these stem cell progenitor cells
throughout the body. Four small case-control studies have
investigated the plasma levels of stromal cell-derived factor 1
in AMD patients with mixed results. Two studies, by the same
group, report significantly lower levels of stromal cell-derived
factor 1 in patients with nAMD,210,211 whereas another study
showed the inverse effect,299 and the fourth did not report any
differences between nAMD and control individuals.115
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
4.2.3. Other cytokines
4.2.3.1. Tumor necrosis factor alpha. Tumor necrosis factor
alpha, an important marker for systemic inflammation, has
been investigated as such in several studies; however, no
significant associations between AMD cases and controls were
reported in serum or plasma.120,124,183,188,231,240,380 Increased
levels of soluble tumor necrosis factor alpha receptor 2 were
reported in a case-control study in early and neovascular
AMD,89 which in a large population-based study did not reach
statistical significance, but there was a trend toward upregulation in early AMD patients.191
4.2.3.2. Interferon gamma. Interferon gamma is an important
cytokine in both innate and adaptive immunity as it induces
cellular response to infections.297 Three studies measured
interferon gamma in AMD cases and controls, but none found
an association with AMD.89,231,240
the affected site. From this perspective, white blood cell count
is an interesting parameter to measure in AMD. A
relatively large number of studies have investigated
white blood cell count in AMD, and some did detect increased
white
blood
cell
numbers.31,181,182,191,307,356
This
contrasts with most studies that did not find any
association.50,113,149,157,180,181,183,185,187,205,285,315,352,367 Nevertheless, white blood cell count may still be considered as a
potential biomarker for AMD if the analysis is performed in
the context of a different theoretical framework. It is
conceivable that it is not the total number of cells that change
but rather the ratio between different cell types. Supporting
this notion, a higher neutrophil/lymphocyte ratio has been
associated to AMD and AMD subtypes.148 A more in-depth
analysis of the different cellular subtypes, such as the relative expression of cytokine/chemokine receptors, would offer
more insights.
4.3.4.
4.3.
Other immune factors
4.3.1.
C-reactive protein
C-reactive protein (CRP) is a marker of inflammation and a socalled acute phase protein because its levels change quickly
upon disturbances of homeostasis. Evidence regarding the
possible relation of this protein with AMD is inconclusive, with a
roughly equal number of studies reporting higher CRP levels in
AMD patients7,56,57,138,174,228,282,290,301,302,304,342,347,356,376 or no clear
evidence for an association.33,58,65,120,134,141,161,185,217,285,312,315,327
Those that used a more precise measurement of CRP (highsensitivity CRP) were also not able to provide conclusive results: 5
studies detected higher levels of high-sensitivity CRP in AMD
patients,32,124,191,230,295 compared with 5 that did not show an
association with AMD.15,183,188,352,367
4.3.2. (Soluble) Intercellular adhesion molecule and vascular
cell adhesion molecule
Intercellular adhesion molecule and vascular cell adhesion
molecule are immunoglobulins that are usually upregulated
on cell surfaces after immune signaling has taken place.48
They form a sticky surface to which immune cells that express integrins can adhere. These molecules and their soluble
counterparts are rarely investigated alone but usually as part
of a panel that measures inflammatory activity. For intercellular adhesion molecule, 1 study reported higher levels to be
associated with the incidence of AMD in women,295 whereas 6
others did not find any association.120,134,183,191,352,367 In the
case of vascular cell adhesion molecule, 1 study measured
higher levels in AMD patients,191 whereas 2 studies did not
find any association with AMD.120,134 In addition, no association with AMD progression and either Intercellular adhesion
molecule or vascular cell adhesion molecule was reported.303
4.3.3.
White blood cell count
As mentioned previously in Section 4, a clear link with
inflammation and inflammatory processes and AMD has been
established, and several immune competent cells have been
implicated in the disease etiology. As a result of local
stress or inflammation, the body may respond by cellular
proliferation of immune cells and recruitment of these cells to
19
Pentraxin-3
Pentraxin-3 (PTX3), like CRP, belongs to the pentraxin superfamily. Upon inflammation, PTX3 is produced locally by the
RPE162 and can interact with complement component C1q and
enhances activation of the classical and lectin pathways of the
complement system. In addition, PTX3 attracts complement
FH, thereby inhibiting the amplification loop and preventing
excessive activation of the alternative pathway.76,162 Although
1 case-control study reported higher plasma PTX3 levels in
nAMD,228 a more recent study (including also early AMD and
GA patients) could not replicate these findings.162 The latter
study did however describe an increased expression of the
PTX3 gene with age- and inflammation-induced apical PTX3
secretion of the RPE.162 Taken together, this suggests a more
local expression of PTX3 in AMD; however, measurements of
PTX3 locally in vitreous samples have not yet been performed
and would therefore be a target of further research.
4.4.
Antibodies
4.4.1.
Antiretinal autoantibodies
The formation of antibodies against foreign epitopes is a key
element of immunity. When endogenous epitopes become the
trigger for mounting an immune response, autoimmunity
ensues.271 Antibodies against epitopes found in retinal material of AMD patients have been investigated in various studies.
Several studies demonstrated upregulation of circulating
antiretinal autoantibodies (ARAs) in the serum of AMD patients.49,119,264,268 Although one study showed similar levels of
ARAs in cases and controls, it did show a difference in types of
antibodies specific for each disease stage.2 In addition, higher
concentrations of circulating ARAs were detected in
treatment-naive nAMD patients compared with controls.196,197 These levels also correlated to lesion size.197 After
the loading phase of anti-VEGF treatment, autoantibody levels
decreased.196,197 Moreover, correlations were reported between ARA levels and improvement of visual acuity, fluid
reduction on optical coherence tomography, and decreased
leakage on fluorescein angiography after 3 months.197
Furthermore, other studies attempted to identify specific
circulating ARAs associated with AMD.145,156,232 Surprisingly,
one study showed not only upregulation of antibodies but also
20
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
downregulation of a specific ARA in AMD. Lower antibody
concentrations were reported for a-crystallin, whereas aenolase and glial fibrillary acidic protein antibodies were both
significantly higher in serum of AMD patients.156 The latter
finding is supported by results from a previous study which
showed different staining patterns in serum of AMD patients,
with the most frequent pattern observed being almost identical to that using antiglial fibrillary acidic protein antibodies.268 In addition, using an untargeted approach, 1 study
identified 4 novel retinal antigens in serum of AMD patients:
retinol binding protein 3 (Rbp3), aldolase C, pyruvate kinase
isoform M2, and retinaldehyde binding protein 1.232 Because
Rbp3 and retinaldehyde binding protein 1 were previously
reported in other ocular diseases, this study focused on
aldolase C and pyruvate kinase isoform M2. A significant
higher reactivity to aldolase C in nAMD, but not in early AMD,
was reported. Because reactivity to pyruvate kinase isoform
M2 was higher in both AMD groups compared with controls,
this could potentially be a biomarker for the development of
AMD.232 A more recent study with a similar approach also
identified ARAs with higher reactivity in AMD; heat shock
70 kDa protein 8 and 9, a-crystallin A chain, annexin A5, and
protein S100-A9.145
4.4.2.
Other autoantibodies
Serum autoantibodies have been extensively investigated by
Morohoshi and colleagues using an antigen microarray analysis containing 85 autoantigens. Serum of AMD patients and
controls showed a different IgG and IgM autoantibody profile,
and multiple autoantibodies were significantly higher in AMD.
In addition, they calculated IgG/IgM ratios for the antibodies
and evaluated whether this ratio correlated to disease
severity. Antiphosphatidylserine IgG/IgM was significantly
elevated in AMD and correlated best with AMD stage. Moreover, reactivity to phosphatidylserine was highly increased in
retina of AMD patients compared with controls.232
Other investigators focused specifically on antiphospholipid antibodies, which are reported to be found in
aging people and diseases associated with aging.257 In this
study, anticardiolipin IgG levels were associated with AMD,
supported by the findings of Morohoshi and colleagues which
showed higher expression of anticardiolipin antibodies in
nAMD compared with controls.233,257
As described in Section 3.1, anti-CEP antibodies have also
been investigated in association with AMD.117,118,242
4.4.3.
Antibodies against pathogens
Infection by pathogens leads to increased antibody titers of
the foreign pathogen. Several infectious agents have been
implicated in AMD, and we detail the antibodies against these
pathogens in this section.
Chlamydia pneumoniae is an intracellular bacterial species
that has been linked to atherosclerosis.137 Since AMD involves
inflammatory processes similar to atherosclerosis, the association of Chlamydia pneumoniae with AMD was explored. One
small case-control study found support for this with increased
antibody levels in AMD patients,167 whereas 4 larger studies
did not find evidence for a relation between anti-Chlamydia
pneumoniae antibodies and AMD.183,188,227,283
The cytomegalovirus is another infectious agent that has
been hypothesized to be associated with the pathogenesis of
AMD, based on the relation between inflammatory processes
induced by infection and the resulting vasculopathy.227 Only 2
studies investigated this association. One found no evidence
for an association,90 whereas the other described higher levels
of antibodies against cytomegalovirus in nAMD compared
with controls and dry AMD.227
Another infectious agent possibly involved in the pathogenesis of AMD is Helicobacter pylori. Two studies have tested
an association between antibodies against Helicobacter pylori
and AMD but found no evidence for this, even when distinguishing between dry and neovascular AMD.188,227
To summarize the most important findings regarding
immune-related factors, involvement of the complement
system in AMD is evident and complement activation products seem to be good biomarker candidates. Increased levels
of inflammatory factors, such as CCL2 or CRP, have been
frequently reported and support the notion that inflammatory
processes underlie AMD. Yet, these are not specifically related
to AMD and may therefore not be the best biomarker for
clinical implementation. The use of multiplex assays for the
simultaneous detection of multiple inflammatory markers
(cytokines and chemokines) holds great promise, but additional data are required to determine their usefulness as AMD
biomarkers. In addition, ARAs are also associated with AMD,
but at present, it is unclear whether these autoantibodies play
a direct role in the etiology of the disease or rather are the
result of retinal damage. Further research is therefore
necessary to determine if (specific) ARAs could be used as a
biomarker for AMD.
5.
Lipid metabolism/homeostasis
Lipid metabolism is one of the major pathways involved in the
pathogenesis of AMD as evidenced by genetic associations of
lipid-linked genes CETP, LIPC, ABCA1, and APOE.99,101 Moreover, drusen, the major hallmark of AMD, consists of at least
40% lipids.126,350 In addition, as mentioned in Section 4.4, there
are similarities in the pathogenesis of atherosclerosis and
AMD.368 Because lipids are important risk factors for atherosclerosis and CVD,207 these might also be associated with
AMD. Numerous studies have measured lipid levels in serum
or plasma, and the results of these studies are summarized in
Sections 5.1 to 5.4. We focus on studies that reported associations with AMD and results from large population-based
studies. A complete overview of all studies and references is
provided in Supplementary Table 4.
5.1.
Lipids
Cholesterol has multiple functions. It is required for building
and maintaining cell membranes, is involved in cell signaling
processes, and is a precursor molecule for synthesis of steroid
hormones, bile acids, and vitamin D.131
The population-based Cardiovascular Health Study reported lower levels of total cholesterol in AMD patients, of
which the majority had early AMD.185,217 Also in the Beaver
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Dam Eye Study, lower cholesterol levels were associated with
development of early AMD in women,182 and there was a trend
for lower levels of cholesterol in nAMD186; a more recent
analysis of the Beaver Dam Eye Study data, however, did not
show an association between AMD and cholesterol levels.183 In
addition, 2 case-control studies described lower levels of
cholesterol in AMD patients.36,267 In contrast, higher cholesterol was associated with AMD in 10 studies, although these
were all case-control studies, and only half studied
nAMD.8,57,67,88,97,109,134,152,246,342 The vast majority of studies
(Supplementary Table 4), however, did not demonstrate a
difference in cholesterol levels between AMD patients
and controls, including a meta-analysis of 3 large populationbased studies,190 and several large population-based
studies.33,37,42,50,61,73,141,143,157,160,161,176,177,184,199,261,304,306,321,331,
345,354,367,371
Triglycerides are molecules that have a glycerol backbone
connected to 3 fatty acids of variable length. Most studies did
not report differences in triglyceride levels between AMD
cases and controls (Supplementary Table 4). Lower triglyceride levels were reported in early AMD,185,371 nAMD,219 and any
AMD.33,177,265,285,304 In contrast, 3 studies reported a higher
level of triglycerides to be associated with AMD,67,235,246 of
these, 1 study included only women,245 and 1 study found the
association in women only.235
Phospholipids are another class of lipids and are an important component of cell membranes. In 3 studies, no association
was found between phospholipids and AMD.1,40,292
5.2.
Lipoproteins
Because of the insoluble nature of lipid molecules, lipoproteins are needed for transportation of lipids through the
circulation. Five different lipoproteins exist, differing in their
density and size: chylomicrons, very lowedensity lipoprotein,
intermediate-density lipoprotein, LDL, and HDL.255 Both HDL
and LDL carry cholesterol between the liver and periphery.131,208,265 The association between these 2 lipoproteins and
AMD has been extensively studied.
For AMD, higher levels of LDL-C were found in several
studies. Half of these studies found this association when
comparing controls to nAMD,109,152,154,279,342 others found an
association in early AMD,273 any AMD,57,67 and in women with
dry AMD.246 Almost all other studies, including multiple large
population-based studies,33,37,50,61,184,304,331,354,371,377 did not
report an association between AMD and LDL-C
(Supplementary Table 4). Only the Cardiovascular Health
Study associated lower LDL-C levels with early AMD patients185 and reported a trend toward lower levels in patients
with any AMD.217 Differences in results regarding LDL-C levels
can be partly due to different measurement methods across
studies, as it can either be measured directly, but more often is
estimated using the Friedewald equation.98
Since HDL cholesterol (HDL-C) is inversely associated with
CVD, one may have expected to also find this inverse association with AMD. Surprisingly, lower HDL-C levels were only
described in a few studies in varying AMD stages; in late
AMD,279,331 in women with dry AMD,246 and in early AMD.180
Increased HDL-C levels in AMD patients were present in
multiple studies.15,35,50,61,73,141,144,161,182,184,186,265,304,345,356,376 It
21
must be noted that most of these studies only found a weak
association in a subgroup of AMD patients. Most of the studies
did not describe significant differences in HDL-C levels
(Supplementary Table 4).
Three studies evaluated non-HDL-C, which is calculated by
subtracting HDL-C from total cholesterol. Two studies,
including a large meta-analysis of 3 population-based studies,
reported no association with AMD,190,265 whereas the third
study found higher non-HDL-C to be associated with any
AMD.57
Lipoprotein (a), Lp(a), is an LDL-like particle, which consists
of apolipoprotein-B100 and apoliprotein-A. Its precise function is unclear, but higher levels of Lp(a) have been repeatedly
associated with CVD.82,171 Contrarily, no association of Lp(a)
levels with AMD or progression of AMD has been described so
far.1,57,83,94,185,246,303
5.3.
Apolipoproteins
Apolipoproteins bind lipids to form lipoproteins that are
responsible for lipid transport. They also function as enzyme
cofactors and receptor ligands.1 There are several classes of
apolipoproteins. The overview presented in this section is
restricted to apolipoprotein A1 (ApoA1), the major component
of HDL-C, apolipoprotein B (ApoB), mostly found in LDL-C, and
apolipoprotein E (ApoE), found in IDL-C and chylomicrons.
Several investigations found an association between apolipoproteins and AMD or features of AMD.1,73,94,246,265 The Pathologies Oculaires Liées à l’Age (POLA) study described
ApoA1 to be associated with an increased risk of soft drusen73
and also in the European Genetic Database (EUGENDA) cohort,
higher levels of ApoA1 were associated with AMD, even after
adjustment for genetic variants that influence lipid levels.265
In contrast, one study reported a lower ApoA1 concentration
in women with dry AMD.246 This study also described a higher
concentration of ApoB in dry AMD cases, which is in concordance with another study.94 Higher ApoE levels were reported
in advanced AMD compared with early AMD and control individuals; this difference could be due to a higher allelic
burden of the APOE gene in these patients.1 Other studies did
not describe an association between ApoA1, ApoB, or ApoE
and AMD.57,66,83,185
5.4.
Fatty acids
There are different types of fatty acids. PUFAs usually derive
from phospholipids or triglycerides.245,254 The most
commonly studied PUFAs in AMD are the omega-3 fatty acids
DHA and eicosapentaenoic acid (EPA). Fish and other seafood
are the main source of these omega-3 PUFAs.219,221 Animal
and epidemiological studies have shown a lower risk for AMD
in subjects with high dietary intake of omega-3 fatty
acids.21,324 Also 2 interventional studies with omega-3 fatty
acid supplementation have been performed; the Age-related
Eye Disease Study 2 showed no beneficial effect for omega-3
fatty acid supplementation,3 whereas the Nutritional AMD
Treatment 2 study showed a protective effect for DHA supplementation only in patient homozygous for the major allele
(T) of the Y402H variant in the CFH gene.222
22
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Considering omega-3 fatty acids as potential biomarkers, a
number of studies investigated plasma or serum levels of
these factors. In the Antioxydants, Lipides Essentiels, Nutrition et maladies Oculaires (ALIENOR), a population-based
study, advanced AMD cases had lower plasma levels of alinoleic acid and DHA compared with no or early AMD. In
addition, lower plasma levels of EPA were associated with
GA.221 This is in line with baseline measurements performed
in the Nutritional AMD Treatment 2 study that showed that
nAMD cases had lower EPA and DHA levels in red blood cell
membranes and lower serum EPA.219 On the contrary, smaller
case-controls studies reported no effect or opposite effects for
DHA, EPA, and a-linoleic acid.165,252,254,292 For plasma or serum
levels of docosapentaenoic acid, another omega-3 fatty acid,
no significant associations were described.165,221,292
Omega-6 fatty acids, arachidonic acid and linoleic acid, and
omega-9 fatty acid, oleic acid, have also been measured. A small
case-control study found lower levels of linoleic acid and oleic
acid, and higher levels of arachidonic acid in the membranes of
erythrocytes of AMD patients.254 In line with these findings, a
recent study reported higher serum arachidonic acid in nAMD.252
Two larger case-control studies, however, did not show different
levels of these omega-6 and omega-9 fatty acids.165,292
Regarding saturated fatty acids (which are single bonded),
lower levels of palmitic acid in erythrocytes of AMD patients
were reported in a small, case-control study,254 although
systemic levels were not different between cases and controls.165,254 Also for stearic acid, no association with AMD was
detected.165,254
Evidence for the involvement of lipids in AMD comes from
epidemiologic, molecular, and genetic studies, but the exact
role of systemic lipid levels is not yet clear. These studies are
complicated by high variability of lipid and fatty acid levels in
general and are potentially further confounded by the use of
medication and/or dietary intake, including supplements.
Although a combination of factors could constitute a risk
profile that may be linked to the development and progression
of AMD, it is unlikely that these factors individually could act
as proper biomarkers for the disease.
6.
Extracellular matrix
Remodeling of the ECM plays a role in the pathogenesis of
AMD.158,241 Drusen development, as well as alterations of
Bruch membrane52,59 and infiltration of immune cells, relate
to a balance between structural tightness or looseness of the
extracellular environment. The constant remodeling of the
ECM is carefully regulated by matrix metalloproteinases
(MMPs) and tissue inhibitors of metalloproteinases.236 Dysregulation of MMPs and/or tissue inhibitors of metalloproteinases could lead to ECM changes seen in AMD, and
therefore, these are potentially useful biomarkers for AMD.
Genetic variations in several ECM-related genes are associated with AMD99,101,275; however, only few studies have
measured plasma or serum levels of MMPs and tissue inhibitors of metalloproteinases.45,46,120,188,381 An overview of
the studies and references is provided in Supplementary Table
5. Upregulation of MMP9 in plasma was associated with AMD
in 1 study45; however, 2 other studies could not replicate these
findings.120,381 No association was found for serum MMP1
levels120,381 or MMP2 in serum or plasma.45,120,381
All 3 studies were limited because of small samples sizes
and the measurement techniques used. Moreover, in these
studies, both the proenzyme and active forms were measured
together. Increased immunoactivity of MMPs does not
necessarily mean an increase in enzymatic activity. Other
measurement techniques are required to measure MMP activity more reliably, and larger future studies are needed to
elucidate the potency of MMPs as biomarkers for AMD.
One of the main constituents of the ECM in Bruch membrane is elastin.241 Elastin, in combination with other proteins
of the ECM,348 provides strong and long-lasting elasticity to
the Bruch’s membrane. The elastin layer degrades with age,
however, and elastin metabolism may contribute to AMD
where there is frequently thinning and fragmentation of the
elastic layer,52 especially in relationship to choroidal neovascularization.31,133 There is also evidence for abnormal
systemic elastin metabolism in AMD. Patients with nAMD had
significantly increased susceptibility to elastolysis in the
skin.31 Patients with nAMD had significantly higher levels of
serum elastin-derived peptide levels,318 probably due to the
aforementioned elevated levels of MMPs in serum.45 Apart
from elevated elastin peptide fragment levels, sera from patients with AMD contain specific autoantibodies against
elastin and it has been suggested that the IgG/IgM ratio for
elastin, and other, autoantibodies might allow monitoring the
progression of AMD.233 Therefore, analyzing elastin degradation products or autoantibody levels or ratios might be useful
tools as biomarkers, at least for nAMD.
7.
Dietary factors
Known risk factors for AMD include dietary factors, such as low
intake of antioxidants. Some vitamins are antioxidants,
whereas others act as cofactors for enzymes involved in ROS
clearance,333 as detailed in Section 7.1. Trace elements have also
been hypothesized to be involved in the pathogenesis of AMD
and are described in Section 7.2. Another marker influenced by
diet is serum albumin; this is considered to be an indicator of
nutritional status and inflammation and is discussed in Section
7.3. In addition, diet is also an important source for fatty acids
and carotenoids both related to AMD. These are described in
Sections 3.4.2 and 5.4, respectively. A complete overview of the
studies and references is provided in Supplementary Table 6.
7.1.
Vitamins
Vitamin C can act as an ROS scavenger, and it mediates
reactivation of vitamin E.333 When vitamin C hydrolyzes and
reactivates vitamin E, the molecule itself is inactivated, and
hydrolysis by GSH can reactivate vitamin C (Fig. 1).258 Lowered
levels of vitamin C result in less vitamin E conversion to its
active form. In addition, vitamin C itself cannot fulfill its
antioxidant function, and as a consequence ROS production
will rise.258 Vitamin C levels were found to be lower in AMD
patients than those in controls311 and lower in advanced
versus early AMD313; however, most studies do not report an
association between vitamin C and AMD.30,72,87,88,360,375
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Vitamin E is anchored in the plasma membrane and
prevents lipid peroxidation.333 Lower levels of serum vitamin
E in AMD patients were reported.25,214,313,360 However, associations with vitamin E were not conclusive because no
difference in vitamin E levels has been found in several
studies.31,40,72,87,88,224,292,311,322,339
One study reported lower levels of vitamin A in patients with
nAMD.384 However, most studies did not find a significant association between vitamin A levels and AMD.31,72,88,224,292,313,360
B vitamins are essential molecules in homocysteine metabolism and synthesis of methionine. Both vitamin B9 (folate)
and B12 (cobalamin) act as cofactors to convert homocysteine
into methionine.294 In AMD patients, lower serum levels of
vitamin B12 were detected compared with controls.113,168,284
These results were not consistently replicated, as equal levels
of serum vitamin B12 in patients and controls have also been
described.132,247 Folate levels were similar between controls
and AMD patients in all studies.113,132,168,183,247,284
Vitamin D can be produced in the dermis upon sunlight
exposure or can be obtained through diet. For its activity, the
molecule has to be converted into its active form in the liver
and kidney before it can regulate uptake of nutrients such as
iron, calcium, magnesium, and zinc.244 There are inconsistent
results for vitamin D levels in AMD patients. They have been
described to be higher,177 lower,150,259 or not associated with
the disease.50,62,111,226,234,261,316
7.2.
Trace elements
Trace elements are required by the human body in very low
concentrations for proper physiological functioning; however,
deficiency or excess amounts may be harmful.27
Iron is essential for retinal functioning, as phototransduction is dependent on iron-containing enzymes.
Accumulation of iron, however, can be harmful. Iron can
convert hydrogen peroxide (H2O2) into highly reactive ROS and
thereby enhance oxidative stress.323 Cadmium can also increase ROS formation361 and mercury can decrease oxidant
defense mechanisms,140 both leading to increased oxidative
stress. In contrast, manganese, copper, and zinc contribute to
antioxidant activity as they are cofactors for the antioxidant
enzyme SOD.333,362 GSHP is dependent on the presence of the
essential heavy metal selenium.17 In addition, copper and zinc
are able to stabilize proteins, reducing their vulnerability to
oxidation362 but can also lead to pathological aggregation or
even precipitation of proteins.237e239 Both zinc and manganese can reduce uptake or accumulation of toxic cadmium.293
Several studies reported elevated cadmium levels in
blood,50,176,262,366 aqueous humor,163 and urine of AMD patients.366 Measurement of cadmium levels in blood might
represent only recent cadmium exposure, whereas urinary
cadmium reflects long-term exposure to cadmium and might
therefore be a more accurate biomarker. A study comparing
both blood and urinary cadmium levels did not show an association with AMD in the total study group; however, when
stratified for smoking status, increased urinary cadmium levels
were associated with AMD in smoking individuals, suggesting a
smoke-related association of cadmium with AMD.81 Lead levels
were elevated in serum and urine of both early and advanced
AMD,50,262,366 and 1 study reported an association between lead
23
and AMD only for women.143 Levels of mercury were only
elevated in patients with advanced AMD.50,262
Selenium was in general not associated with AMD.87,88,163
One study found a borderline significant association with
AMD,339 and another measured significantly lower levels of
selenium in nAMD patients.216 Conflicting results are reported
for levels of iron,31,163,369 copper,40,163 manganese,163,262 and
zinc.24,88,163,262,313
7.3.
Albumin
Albumin is essential for maintenance of plasma colloid
oncotic pressure, acts as a plasma binding protein, and also
has antioxidant activity.202 In addition, albumin is one of the
most common proteins found in drusen.63 A few studies
measured serum albumin in AMD patients and controls. Two
case-control studies did not show a significant association
between serum albumin and AMD.31,88 The population-based
Cardiovascular Health Study and Beaver Dam Eye Study did
report significantly lower serum albumin levels in early and
neovascular AMD, respectively.185,187 A more recent nested
case-control study within the Beaver Dam population further
analyzing these data could not confirm decreased albumin
levels in AMD.183
Taken together, because of the highly variable diet
between subjects, and varying levels of dietary factors within
subjects based on fasting state, assessment of the role of these
dietary factors as biomarkers in AMD remains difficult.
Dietary intake and/or supplementation of antioxidants and
vitamins, however, have therapeutic benefit. The Age-related
Eye Disease Study trial, one of the largest investigations into
vitamin supplementation in AMD, focused on daily supplementation with vitamin E, vitamin C, b-carotene, and zinc and
demonstrated a lower chance of advanced AMD development
in subjects taking these supplements.4 In the Age-related Eye
Disease Study 2, an improved formula was evaluated and
b-carotene was replaced by lutein/zeaxanthin because of the
increased risk of lung cancer in smokers.3,5
Regarding trace elements, toxic heavy metals (such as lead,
mercury, and cadmium) are mainly associated with an
increased risk of AMD, whereas essential heavy metals (e.g.,
zinc and manganese) seem to protect against the development of AMD. For most trace elements, there are only a
limited number of studies available in the public domain to
date, and further research is required to assess their potential
role as a biomarker or as protective supplement.
8.
Hormones
In this section, we discuss the few hormones that have been
investigated in relation to AMD: leptin, melatonin, and dehydroepiandrosterone sulfate (DHEAS). A complete overview of the
studies and references is provided in Supplementary Table 7.
8.1.
Leptin
Because AMD is a multifactorial disease in which dietary factors
and body mass index also play a role in the disease mechanism,
it has been suggested that the principal hormone involved in
24
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
food intake behavior, leptin, may be associated with AMD. Two
studies support this theory; both showed a reduction in serum
leptin levels in AMD patients compared with controls.85,306 After
controlling for potential confounders, including smoking, body
mass index, blood pressure, and HDL-C, the association
remained significant, which suggests that mechanisms other
than body fat underlie the relationship between leptin levels and
AMD.306 The third study did not observe a difference in leptin
levels in patients versus control individuals.124
8.2.
Melatonin
Melatonin has strong antioxidative capacities, is expressed in
the retina, and expression levels decrease during
aging.173,276,277 Two studies investigated the levels of melatonin in AMD. One showed elevated blood levels of daytime
melatonin in pseudophakic AMD patients.296 The second
study analyzed the major metabolite of melatonin in urine, 6sulfatoxymelatonin, and described lower levels in AMD.286
Comparing the 2 studies is difficult because of the differences in methodology and fluid matrix analyzed, so additional
experiments linking melatonin and AMD are necessary.
8.3.
Dehydroepiandrosterone sulfate
DHEAS is a sulfate ester of DHEA, which is an endogenous
steroid hormone synthesized from cholesterol in the adrenal
glands and serves as precursor molecule for sex steroids,
androgen and estrogen.212 It has been suggested that DHEAS
has antioxidant effects.212,330,342 In addition, the DHEAS level
in blood decreases with age.23,212,330 Since both oxidative
stress and aging are important risk factors for AMD,59 the
question arises whether DHEAS and AMD could be correlated.
Three studies investigated the association between AMD and
DHEAS, all with different outcomes; higher levels of DHEAS
were reported in women with early AMD,69 another study
described low DHEAS in both dry and neovascular AMD
cases,330 and a third study did not find an association between
nAMD and controls.342
In summary, only a limited amount of studies assessing
hormones in AMD have been performed with inconclusive
results and do not seem to be reliable biomarkers for AMD at
this point in time.
9.
Factors related to comorbidities
AMD has been suggested to share risk factors or coexist with
other diseases, such as kidney disease, diabetes mellitus, and
Alzheimer’s disease. Factors related to these comorbidities are
discussed in Sections 9.1e9.3, respectively. Although AMD has
not been associated with liver disease before, some studies
investigated factors related to liver function and these are
described in Section 9.4. A complete overview of the studies
and references is provided in Supplementary Table 8.
9.1.
Kidney disease
Several studies have suggested overlapping risk factors between AMD and kidney diseases.77,189,203,356 A number of
large, often population-based, studies have not only investigated kidney function, such as glomerular filtration rate, but
also markers that can be measured in serum/plasma like
creatinine and cystatin-C. In the Beaver Dam Eye Study,
serum cystatin-C was associated to the incidence of early
AMD and nAMD.189 In the Multi-Ethnic Study of Atherosclerosis, this association was only found when the highest
deciles of cystatin-C were compared with other deciles with
prevalence of early AMD.51 In the Hatoyama study, no association between cystatin-C and AMD was found.15
Several large studies investigated creatinine in patients,
but no clear association between serum creatinine and AMD
was found. Two reports from the Korean National Health and
Nutrition Examination Survey describe a significant difference
between AMD patients and controls, but after adjustment for
other variables, no significant association was found.50,261 The
remainder of the studies, including large population-based
studies such as the Multi-Ethnic Study of Atherosclerosis
and the Singapore Malay Eye Study, did not find
any
association
between
serum
creatinine
and
AMD.31,33,37,150,152,153,247
Another indicator of renal health is blood urea nitrogen,
but also for this factor, no link was established with
AMD.31,50,189,261
9.2.
Diabetes mellitus
Although some cardiovascular risk factors, such as smoking,
have been consistently related to AMD, there are conflicting
results for an association between diabetes mellitus and
AMD.43 Several studies, mostly population-based, measured
glycated hemoglobin and glucose as indicators for the presence of diabetes mellitus. Only one study found lower levels of
glucose in advanced AMD,199 but none of the other studies
described an association of either markers with
AMD.31,33,37,73,88,143,152,153,160,176,321,371,377 Several studies, all
reports from the Korean National Health and Nutrition
Examination Survey, reported lower glycated hemoglobin
levels in AMD50,143,176,177,199; however, studies from other
cohorts detected no difference.33,37,160,342,380
9.3.
Alzheimer’s disease
Similar to AMD, the prevalence of Alzheimer’s disease increases with age. This neurological disorder is characterized by
amyloid plaques in the brain, with the main component being
amyloid beta (Ab).16 In AMD, 2 studies identified Ab as a
component of drusen.12,75 In addition, Ab might trigger activation of the complement cascade in AMD.159 Several isoforms of
Ab with different amino acid lengths exist; in this section, we
discuss the most common isoforms: Ab1-40 and Ab1-42.
A small, case-control study did not show different levels of
Ab1-42 between controls and either dry or neovascular
AMD247; however, 2 more recent case-control studies showed
significantly higher Ab1-42 peptide levels in AMD patients.120,124 Also after correction for age, Ab1-42 was significantly associated with AMD, and there was a trend toward
increasing levels of Ab with increasing disease severity.120 An
association of AMD with Ab1-40 in these studies was less
clear. A significant upregulation was described in one study in
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
nAMD only,120 whereas the other study did not report a difference between nAMD patients and controls.124
9.4.
Liver function
So far, to our knowledge, no study has focused specifically on
liver function and AMD. In a few studies, indicators of liver
function have been reported as part of a routine blood
examination with no associations between lactate dehydrogenase, aspartate transaminase, or alanine transaminase and
AMD.31,50,285
For hepatitis B surface antigen on the other hand, an association was described in several Korean studies, a country
where hepatitis B is still endemic.50,261,285 In these studies,
hepatitis B surface antigen carrier status was positively
associated with AMD. Hepatitis B surface antigen has been
detected in subretinal fluid, and it is hypothesized these individuals are therefore at increased risk for uveoretinal pathology, such as AMD.261,285
In conclusion, despite coexistence and overlapping risk
factors with AMD, biomarkers for kidney disease, diabetes
mellitus, and liver disease discussed here do not seem good
biomarker candidates for AMD. As an exception, Ab could
potentially be a marker of disease progression; however,
larger prospective studies are required to confirm these findings. In addition, also in terms of a potential new drug target,
further evaluation of this biomarker in AMD seems worthwhile, as promising anti-Ab therapies are being developed for
Alzheimer’s disease.16
10.
Hypothesis-free techniques
In the past decade, many advanced high-throughput omic
technologies have been developed. These technologies enable
us to analyze large numbers of markers at the same time in an
untargeted and unbiased manner. Here, we discuss several
omic technologies in association with AMD (Fig. 3): proteomics
(Section 10.1), metabolomics (Section 10.2), and epigenomics
(Section 10.3). Expression of circulating microRNAs can also be
measured using high-throughput techniques; these are
described in Section 10.4.
10.1.
Proteomics
The field of proteomic research uses mass spectrometry, or
variations to this technique, to determine the nature of peptides or proteins in various tissues or other biological samples.
The advantage of proteomic research is that it delivers results
that are unbiased by preconceived notions or hypotheses.
Within the field of AMD, proteomics has been used in a
number of investigations, and several have been successful in
showing particular proteomic signatures in plasma, vitreous,
and aqueous humor from AMD patients when compared with
controls.
A small study by Kim and colleagues identified 154 proteins
in aqueous humor of 9 nAMD patients and 8 cataract controls.178 In this study, 7 potential biomarker candidates were
selected for further analysis: ceruloplasmin, PEDF, plasma
protease C1 inhibitor, TGF-b1, clusterin, cathepsin D, and
25
cystatin D. The relative abundances of TGF-b1, plasma protease C1 inhibitor, ceruloplasmin, and PEDF were shown to be
significantly higher in AMD samples compared with controls.
Another small study, collecting and profiling aqueous humor
of 6 nAMD patients and 6 cataract controls, found 68 proteins
to be differentially expressed.372 Only 9 proteins were identified in both studies, among which were some that were
related to AMD previously (CCL24 and complement FI),
lipocalin-1 and several members of the crystallin family.
These crystallins, known for their chaperone function, may
also be involved in protein-protein interaction, prevention of
apoptosis, and inhibition of inflammation among others.170
Lipocalin-1 concentrations were quantified using enzymelinked immunosorbent assay, and levels were significantly
elevated in the aqueous humor of nAMD patients.
A third small study performed a focused proteomic analysis on protein members of the ubiquitin pathway.201 Difference in expression of 6 proteins in aqueous humor of 2 AMD
patients compared with 2 controls was reported. This
included the 26S proteasome non-ATPase regulatory subunit 1
(Rpn2), a protein that is also present in plasma. Rpn2 was
therefore selected as potential AMD biomarker and liquid
chromatography-multiple reaction monitoring mass spectrometry of another 15 aqueous humor samples showed a
relative increase of Rpn2 in nAMD patients.
Kang and colleagues analyzed aqueous humor samples of
26 treatment naive patients with nAMD and 18 controls.169 By
comparing expression profiles in exosomes of aqueous humor
and cultured RPE cells, 6 candidate proteins were selected for
verification in an independent sample set by liquid
chromatography-multiple reaction monitoring mass spectrometry: actin, myosin-9, heat shock protein 70, cathepsin D,
cytokeratin 8, and cytokeratin 14. Of these, cytokeratin 8
showed the highest area under the curve value (0.929),
suggesting that it is a strong predictor for AMD. Although
cytokeratins were not previously reported in other proteomic
analyses in AMD and might be valuable markers to further
investigate, it is disputable whether they could qualify as
manageable biomarkers. Cytokeratins are abundant contaminants in laboratories,209 so careful replication of these
findings in other laboratories is warranted.
One other study investigated in a targeted manner the
involvement of Wnt modulators in aqueous humor and found
that WNT inhibitory factor 1 (WIF-1) and Dickkopf-related
protein 3 (DKK-3) were upregulated in nAMD.260
In a study of 73 nAMD patients and 15 controls, a large set
of proteins were detected in vitreous humor, of which 19 were
upregulated in nAMD patients.194 Bioinformatic analyses
suggested enrichment of the complement and coagulation
cascades, as well as markers involved in arachidonic acid
metabolism. Of the 19 proteins, 5 were randomly selected for
Western blot validation; alpha-1-antitrypsin reached statistical significance, whereas ApoA1 and transthyretin showed a
nonsignificant increase in AMD. These findings need validation in a larger sample set.
Nobl and colleagues investigated vitreous samples of 108
nAMD patients and 24 controls, distributed over a discovery
and validation set, and discovered 101 different proteins.243
Using a closed testing procedure, they focused on 4 differentially expressed proteins as candidate AMD biomarkers:
26
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
Genomics
Proteomics
Genes
Proteins
Disease
Epigenomics
Metabolomics
Environment
Metabolites
Fig. 3 e Omics in age-related macular degeneration.
clusterin, opticin, PEDF, and PH2D, which were increased in
nAMD compared with controls, except for opticin, which was
reduced. Upregulation of PEDF and PH2D in nAMD was
described previously.178,194 Clusterin and PEDF remained
significantly increased in nAMD after validation and correction for multiple testing in an independent sample set using
enzyme-linked immunosorbent assay.
There have been limited plasma proteomic studies. Xu and
colleagues found 28 clinically relevant proteins to be altered
in AMD patients (N ¼ 24) compared with healthy volunteers
(N ¼ 6),370 but further investigation of these plasma proteins is
necessary to validate these findings. In addition, 2 studies
using proteomic profiling of the same data set identified 3
potential AMD biomarkers: vinculin, phospolipid transfer
protein, and mannan-binding lectin protease-1.175,179 In general, proteomics of plasma or serum is a great analytical
challenge due to the dominant fraction of highly abundant
proteins, which have effectively prevented the discovery of
novel proteomic biomarkers in these fluids in the past.
Therefore, improved technologies are needed. Fortunately,
some progress has been made using quantitative shot-gun
proteomics, recently.108
10.2.
Metabolomics
Metabolomic studies use mass spectrometric technologies or
nuclear magnetic resonance spectroscopy to measure derivatives of metabolism. The technique offers a snapshot of
the physiological state of an organism at the level of body
fluids (urine, tears, serum, and plasma), cells or even tissues.
Metabolomic analysis of AMD has great potential to uncover
novel pathways in the disease that are reflective of the interaction between the genetic blueprint of individual and environmental factors that influence the metabolites (e.g., diet
and smoking). To date, only one metabolome-wide study was
conducted in plasma samples of 26 nAMD patients and 19
controls. Pathway analysis pointed toward involvement of
tyrosine metabolism, urea metabolism, and vitaminDerelated metabolism.253
10.3.
Epigenomics
Although it is clear that both genetic components as well as
environmental elements contribute to the risk of developing
AMD, it is less clear how these 2 systems interact. This
interaction is the domain of epigenetics, induced changes in
the expression levels of genes controlled by outside influences. Epigenetics is a broad term, encompassing many
possible regulatory mechanisms of gene expression. One type
of epigenetic mark that has been explored in a number of
studies is the difference in DNA methylation patterns between
cases and controls.
Epigenetic changes can be observed in peripheral blood
leukocytes, which are relatively easy to obtain. One study
showed a decrease in methylation near the IL17RC promotor
region, suggesting that this could serve as a potential
biomarker for AMD.355 However, the finding could not be
validated by an independent study with a sufficiently powered
study design.249
Based on these results, and also because epigenetic
mechanisms are likely to be tissue specific, the relationship
between DNA methylation patterns in peripheral blood and
retinal tissue was investigated in a recent study.250 Although
no epigenome-wide association peak was observed, the study
did report consistent methylation changes across multiple
samples near the ARMS2 locus and near the protease serine 50
(PRSS50) gene.
Despite a limited sample size, the results provided some
evidence that methylation patterns in blood leukocytes could
serve as proxies for retinal changes, implying that such
studies could deliver additional biomarkers for AMD.250
10.4.
Circulating microRNAs
A microRNA (miRNA) is a small noncoding RNA molecule that
regulates gene expression after transcription, thereby influencing biological processes. These miRNAs are present in
circulation and could potentially serve as biomarkers.229
Because we focus on compounds found in body fluids, only
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
27
Fig. 4 e Flow diagram of literature search. The screening and selection process of studies included for this review is depicted
in the flow diagram.
the studies that investigate circulating miRNAs (cmiRNAs) in
serum or plasma are described here.
In a small study by Ertekin and colleagues,84 plasma samples of 33 nAMD patients and 31 controls were analyzed for the
expression of 384 miRNAs. They found 16 miRNAs to be
differentially expressed between the 2 groups and additionally
discovered 10 miRNAs to be only expressed in nAMD patients.
Grassmann and colleagues identified 203 cmiRNAs in
serum, of which 3 (hsa-mir-301-3p, hsa-mir-361-5p, and hsamir-424-5p) were significantly altered in nAMD patients
(N ¼ 129) compared with control individuals (N ¼ 147).114 No
significant association was found in GA patients (N ¼ 59),
suggesting different mechanisms for advanced AMD subtypes. Pathway analysis of the genes that are likely regulated
by the altered cmiRNAs implicated the mTOR and TGF-b
pathways in nAMD and knockdown of these cmiRNAs in vitro
resulted in increased angiogenesis but only significantly for
hsa-mir-361-5p.
Szemraj and colleagues also reported significant differences in cmiRNA profiles between dry and neovascular AMD
patients.328 In this study, serum expression levels of 377
miRNA genes in 300 AMD patients (150 nAMD/150 dry AMD
patients) and 200 control individuals were analyzed. This
study identified 31 differentially expressed miRNAs between
patients and controls, including 2 of the 3 previously associated114 cmiRNAs (hsa-mir-301-5p and hsa-mir-424-5p). Of the
differentially expressed miRNAs in this study, 5 were significantly different between patients with dry and neovascular
AMD. In addition, the correlation between these miRNAs and
expression of VEGF and VEGFR2 was assessed, and it was
suggested that miRNA Let-7 is implicated in the neoangiogenesis in nAMD.
So far, limited studies on miRNA profiling in AMD have
been performed and results need to be replicated in larger
studies; however, these initial findings emphasize the potential of cmiRNAs as biomarkers in AMD.
In general, studies using hypothesis-free techniques
demonstrate proof of concept that omic analyses are able to
identify novel biomarkers for AMD; however, more are needed
to validate results and to confirm the clinical utility of these
biomarkers.
11.
Conclusion and future directions
In summary, numerous compounds have been analyzed in
relation to AMD. However, only a few of these have potential
as AMD biomarkers. The most promising biomarker candidates belong to the oxidative stress pathway, the complement
system, and to a lesser extent, lipid metabolism. Finally, the
use of hypothesis-free techniques in biomarker detection
holds great promise. For summarized findings regarding factors belonging to the other biological pathways described in
this review, we refer to the closing paragraphs of the respective chapters. As of yet, none of the biomarkers that we have
reviewed here are used clinically.
Many studies reported decreased antioxidant levels and
elevated levels of oxidized proteins or lipids indicating
oxidative stress in AMD. MDA is often used as a marker for
lipid peroxidation, and increased levels of MDA have been
very consistently observed in both wet and dry AMD (11 of 11
studies, Section 3.1). In addition, most studies reported higher
levels of homocysteine, an intermediate in the oxidative
stress pathway, in AMD (12 of 18 studies, Section 3.3). Besides
28
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
dysregulation of the oxidative stress pathway, many studies
indicate the involvement of the complement system in AMD.
Products of complement activation and levels of complement
activationddescribed by the ratio of C3 and its degradation
product C3d (C3d/C3)dwere repeatedly associated with AMD
(Section 4.1). In addition, there is clear involvement of lipids in
AMD from genetic and molecular studies; however, the role of
systemic lipids in AMD is not fully elucidated, and therefore,
they are not yet applicable as robust biomarkers for the
disease.
In general, many inconsistencies exist between studies
evaluating biomarkers and their association with AMD. The
contradicting results are difficult to interpret due to a variety
of differences between studies, including methodological
differences (fasting vs nonfasting blood), different
populations (Caucasian/Asian/Mediterranean) with different
dietary habits, different study designs, different analytical
methods, and correction factors, but also types of AMD
included in the studies. It must be noted that compiling and
comparison of data deriving from different sources represent
a major limitation. Therefore, large well-conducted prospective studies are needed to further clarify these results.
Although AMD represents a phenotype restricted to the
eye, many studies have investigated systemic markers in
relation to AMD; however, because of the presence of the
blood-retinal barrier, biomarkers might be only locally
dysregulated inside the eye without a measurable systemic
effect. In addition, some compounds are differently expressed
between tissues, leading to different results when analyzing
different matrices. One might therefore argue to measure
markers only locally; however, because of the invasive character and accompanying ethical issues, systemic markers are
preferred for implementation as clinical biomarkers.
Until now, most studies have targeted specific single biomarkers in a candidate-driven approach. Omic studies with an
unbiased view are heavily outnumbered. Future biomarker
research should therefore combine hypothesis-free as well as
candidate-driven approaches. Quantitative analytical approaches applied in an untargeted and targeted fashion, such as
metabolomic or proteomic studies, are necessary to identify
novel biomarker candidates. Once validated as robust and reliable markers, they can offer more insights into the etiology and
pathogenesis of AMD and support prediction, diagnosis, stratification, monitoring of treatment, and drug development for AMD.
Other biomarker types in AMD such as genetic factors,
imaging biomarkers, or visual function measurements are
currently of key importance for proper clinical diagnosis,
stratification, and treatment of AMD. In the future, these
established clinical examinations and diagnostic tests may
well be applied in combination with molecular biomarkers, an
area which is still in a nascent stage.
12.
Methods of literature search
A review of literature was performed through a thorough
PubMed search in November 2015. We used the following
keywords and their synonyms in various combinations: agerelated macular degeneration, serum, plasma, blood, urine,
tear, aqueous, and vitreous. No limitations were set for the
time range covered by our search, and therefore, all articles
published until our search were included.
All abstracts were screened for relevance and full texts of
the selected articles were studied. We included only articles
written in English. Articles cited in the reference lists of articles
obtained through this search were also included whenever
relevant. Animal, ex vivo, and in vitro studies were excluded.
To include the most recent developments before submission,
the search was repeated in June 2016. An overview of our selection process is detailed in Fig. 4.
After the final article selection, all described compounds in
these studies were grouped based on their common biological
function or pathway, and results were discussed accordingly.
Of note, compounds that were only described once in literature were not mentioned in this review to reduce the effect of
selective reporting.
13.
Disclosures
The authors do not report any proprietary or commercial interest in the subject matter of this paper.
Acknowledgment
The authors wish to acknowledge the support of the EYE-RISK
Consortium. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634479.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.survophthal.2017.05.003.
references
1. Abalain JH, Carre JL, Leglise D, et al. Is age-related macular
degeneration associated with serum lipoprotein and
lipoparticle levels? Clin Chim Acta. 2002;326(1-2):97e104
2. Adamus G, Chew EY, Ferris FL, Klein ML. Prevalence of
anti-retinal autoantibodies in different stages of
Age-related macular degeneration. BMC Ophthalmol.
2014;14:154
3. Age-Related Eye Disease Study 2 Research G. Lutein þ
zeaxanthin and omega-3 fatty acids for age-related macular
degeneration: the Age-Related Eye Disease Study 2 (AREDS2)
randomized clinical trial. JAMA. 2013;309(19):2005e15
4. Age-Related Eye Disease Study Research G. A randomized,
placebo-controlled, clinical trial of high-dose
supplementation with vitamins C and E, beta carotene, and
zinc for age-related macular degeneration and vision loss:
AREDS report no. 8. Arch Ophthalmol.
2001;119(10):1417e36
5. Age-Related Eye Disease Study 2 Research G, Chew EY,
Clemons TE, et al. Secondary analyses of the effects of
lutein/zeaxanthin on age-related macular degeneration
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
progression: AREDS2 report No. 3. JAMA Ophthalmol.
2014;132(2):142e9
Albanes D, Heinonen OP, Taylor PR, et al. Alpha-Tocopherol
and beta-carotene supplements and lung cancer incidence
in the alpha-tocopherol, beta-carotene cancer prevention
study: effects of base-line characteristics and study
compliance. J Natl Cancer Inst. 1996;88(21):1560e70
Ambreen F, Ismail M, Qureshi IZ. Association of gene
polymorphism with serum levels of inflammatory and
angiogenic factors in Pakistani patients with age-related
macular degeneration. Mol Vis. 2015;21:985e99
Ambreen F, Khan WA, Qureshi N, Qureshi IZ. Assessment of
serum lipids in patients with age related macular
degeneration from Pakistan. J Pak Med Assoc.
2014;64(6):664e9
Anand A, Sharma NK, Gupta A, et al. Single nucleotide
polymorphisms in MCP-1 and its receptor are associated
with the risk of age related macular degeneration. PLoS One.
2012;7(11):e49905
Anand A, Sharma NK, Gupta A, et al. Superoxide dismutase1
levels in North Indian population with age-related macular
degeneration. Oxid Med Cell Longev. 2013;2013:365046
Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role
for local inflammation in the formation of drusen in the
aging eye. Am J Ophthalmol. 2002;134(3):411e31
Anderson DH, Talaga KC, Rivest AJ, et al. Characterization of
beta amyloid assemblies in drusen: the deposits associated
with aging and age-related macular degeneration. Exp Eye
Res. 2004;78(2):243e56
Angiolillo AL, Sgadari C, Taub DD, et al. Human interferoninducible protein 10 is a potent inhibitor of angiogenesis
in vivo. J Exp Med. 1995;182(1):155e62
Ansari M, McKeigue PM, Skerka C, et al. Genetic influences
on plasma CFH and CFHR1 concentrations and their role in
susceptibility to age-related macular degeneration. Hum Mol
Genet. 2013;22(23):4857e69
Aoki A, Tan X, Yamagishi R, et al. Risk Factors for AgeRelated Macular Degeneration in an Elderly Japanese
Population: the Hatoyama Study. Invest Ophthalmol Vis Sci.
2015;56(4):2580e5
Arbor SC, LaFontaine M, Cumbay M. Amyloid-beta
Alzheimer targets - protein processing, lipid rafts, and
amyloid-beta pores. Yale J Biol Med. 2016;89(1):5e21
Arthur JR. The glutathione peroxidases. Cell Mol Life Sci.
2000;57(13-14):1825e35
Ates O, Azizi S, Alp HH, et al. Decreased serum paraoxonase
1 activity and increased serum homocysteine and
malondialdehyde levels in age-related macular
degeneration. Tohoku J Exp Med. 2009;217(1):17e22
Axer-Siegel R, Bourla D, Ehrlich R, et al. Association of
neovascular age-related macular degeneration and
hyperhomocysteinemia. Am J Ophthalmol. 2004;137(1):84e9
Bai Y, Liang S, Yu W, et al. Semaphorin 3A blocks the
formation of pathologic choroidal neovascularization
induced by transforming growth factor beta. Mol Vis.
2014;20:1258e70
Barker FM 2nd, Snodderly DM, Johnson EJ, et al. Nutritional
manipulation of primate retinas, V: effects of lutein,
zeaxanthin, and n-3 fatty acids on retinal sensitivity to bluelight-induced damage. Invest Ophthalmol Vis Sci.
2011;52(7):3934e42
Baskol G, Karakucuk S, Oner AO, et al. Serum paraoxonase 1
activity and lipid peroxidation levels in patients with agerelated macular degeneration. Ophthalmologica.
2006;220(1):12e6
Baulieu EE, Thomas G, Legrain S, et al.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging:
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
29
contribution of the DHEAge Study to a sociobiomedical
issue. Proc Natl Acad Sci U S A. 2000;97(8):4279e84
Beatty S, Koh H, Phil M, et al. The role of oxidative stress in
the pathogenesis of age-related macular degeneration. Surv
Ophthalmol. 2000;45(2):115e34
Belda JI, Roma J, Vilela C, et al. Serum vitamin E levels
negatively correlate with severity of age-related macular
degeneration. Mech Ageing Dev. 1999;107(2):159e64
Bertelmann T, Spychalska M, Kohlberger L, et al.
Intracameral concentrations of the fibrinolytic system
components in patients with age-related macular
degeneration. Graefes Arch Clin Exp Ophthalmol.
2013;251(12):2697e704
Bhattacharya PT, Misra SR, Hussain M. Nutritional
Aspects of Essential Trace Elements in Oral Health and
Disease: An Extensive Review. Scientifica (Cairo).
2016;2016:5464373
Bhutto IA, Baba T, Merges C, et al. Low nitric oxide synthases
(NOSs) in eyes with age-related macular degeneration
(AMD). Exp Eye Res. 2010;90(1):155e67
Binder BR, Christ G, Gruber F, et al. Plasminogen activator
inhibitor 1: physiological and pathophysiological roles. News
Physiol Sci. 2002;17:56e61
Biomarkers Definitions Working G. Biomarkers and
surrogate endpoints: preferred definitions and conceptual
framework. Clin Pharmacol Ther. 2001;69(3):89e95
Blumenkranz MS, Russell SR, Robey MG, et al. Risk factors in
age-related maculopathy complicated by choroidal
neovascularization. Ophthalmology. 1986;93(5):552e8
Boekhoorn SS, Vingerling JR, Witteman JC, et al. C-reactive
protein level and risk of aging macula disorder: The
Rotterdam Study. Arch Ophthalmol. 2007;125(10):1396e401
Boey PY, Tay WT, Lamoureux E, et al. C-reactive protein and
age-related macular degeneration and cataract: the
singapore malay eye study. Invest Ophthalmol Vis Sci.
2010;51(4):1880e5
Bosevski M, Borozanov V, Peovska I, Georgievska-Ismail L.
Endothelial dysfunction correlates with plasma fibrinogen
and HDL cholesterol in type 2 diabetic patients with
coronary artery disease. Bratisl Lek Listy.
2007;108(7):297e300
Brantley MA Jr, Osborn MP, Sanders BJ, et al. Plasma
biomarkers of oxidative stress and genetic variants in agerelated macular degeneration. Am J Ophthalmol.
2012;153(3):460e7.e1
Butt AL, Lee ET, Klein R, et al. Prevalence and risks factors of
age-related macular degeneration in Oklahoma Indians: the
Vision Keepers Study. Ophthalmology. 2011;118(7):1380e5
Cackett P, Wong TY, Aung T, et al. Smoking, cardiovascular
risk factors, and age-related macular degeneration in
Asians: the Singapore Malay Eye Study. Am J Ophthalmol.
2008;146(6):960e7.e1
Cai J, Nelson KC, Wu M, et al. Oxidative damage and
protection of the RPE. Prog Retin Eye Res. 2000;19(2):205e21
Camelo S. Potential Sources and Roles of Adaptive Immunity
in Age-Related Macular Degeneration: Shall We Rename
AMD into Autoimmune Macular Disease? Autoimmune Dis.
2014;2014:532487
Cardinault N, Abalain JH, Sairafi B, et al. Lycopene but not
lutein nor zeaxanthin decreases in serum and lipoproteins
in age-related macular degeneration patients. Clin Chim
Acta. 2005;357(1):34e42
Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial
growth factor plasma levels before and after treatment of
neovascular age-related macular degeneration with
bevacizumab or ranibizumab. Acta Ophthalmol.
2012;90(1):e25e30
30
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
42. Chaker L, Buitendijk GH, Dehghan A, et al. Thyroid function
and age-related macular degeneration: a prospective
population-based cohort studyethe Rotterdam Study. BMC
Med. 2015;13:94
43. Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular
degeneration. BMJ. 2010;340:c981
44. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk
factors for age-related macular degeneration: a systematic
review and meta-analysis. BMC Ophthalmol. 2010;10:31
45. Chau KY, Sivaprasad S, Patel N, et al. Plasma levels of matrix
metalloproteinase-2 and -9 (MMP-2 and MMP-9) in agerelated macular degeneration. Eye (Lond).
2007;21(12):1511e5
46. Chau KY, Sivaprasad S, Patel N, et al. Plasma levels of matrix
metalloproteinase-2 and -9 (MMP-2 and MMP-9) in agerelated macular degeneration. Eye (Lond). 2008;22(6):855e9
47. Chelikani P, Fita I, Loewen PC. Diversity of structures and
properties among catalases. Cell Mol Life Sci.
2004;61(2):192e208
48. Chen H, Liu C, Sun S, et al. Cytokine-induced cell surface
expression of adhesion molecules in vascular endothelial
cells in vitro. J Tongji Med Univ. 2001;21(1):68e71
49. Cherepanoff S, Mitchell P, Wang JJ, Gillies MC. Retinal
autoantibody profile in early age-related macular
degeneration: preliminary findings from the Blue Mountains
Eye Study. Clin Exp Ophthalmol. 2006;34(6):590e5
50. Cho BJ, Heo JW, Kim TW, et al. Prevalence and risk factors of
age-related macular degeneration in Korea: the Korea
National Health and Nutrition Examination Survey 20102011. Invest Ophthalmol Vis Sci. 2014;55(2):1101e8
51. Chong EW, Guymer RH, Klein R, et al. Is renal function
associated with early age-related macular degeneration?
Optom Vis Sci. 2014;91(8):860e4
52. Chong NH, Keonin J, Luthert PJ, et al. Decreased thickness
and integrity of the macular elastic layer of Bruch’s
membrane correspond to the distribution of lesions
associated with age-related macular degeneration. Am J
Pathol. 2005;166(1):241e51
53. Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidationspecific epitopes are dominant targets of innate natural
antibodies in mice and humans. J Clin Invest.
2009;119(5):1335e49
54. Christen WG, Cook NR, Ridker PM, Buring JE. Prospective
study of plasma homocysteine level and risk of age-related
macular degeneration in women. Ophthalmic Epidemiol.
2015;22(2):85e93
55. Cohen SM, Olin KL, Feuer WJ, et al. Low glutathione
reductase and peroxidase activity in age-related macular
degeneration. Br J Ophthalmol. 1994;78(10):791e4
56. Cohn AC, Busija L, Robman LD, et al. Younger siblings, Creactive protein, and risk of age-related macular
degeneration. Am J Epidemiol. 2013;177(9):933e43
57. Colak E, Kosanovic-Jakovic N, Zoric L, et al. The association
of lipoprotein parameters and C-reactive protein in patients
with age-related macular degeneration. Ophthalmic Res.
2011;46(3):125e32
58. Colak E, Majkic-Singh N, Zoric L, et al. The impact of
inflammation to the antioxidant defense parameters in AMD
patients. Aging Clin Exp Res. 2012;24(6):588e94
59. Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related
macular degeneration. Lancet. 2008;372(9652):1835e45
60. Coral K, Raman R, Rathi S, et al. Plasma homocysteine and
total thiol content in patients with exudative age-related
macular degeneration. Eye (Lond). 2006;20(2):203e7
61. Cougnard-Gregoire A, Delyfer MN, Korobelnik JF, et al.
Elevated high-density lipoprotein cholesterol and agerelated macular degeneration: the Alienor study. PLoS One.
2014;9(3):e90973
62. Cougnard-Gregoire A, Merle BM, Korobelnik JF, et al. Vitamin
D Deficiency in Community-Dwelling Elderly Is Not
Associated with Age-Related Macular Degeneration. J Nutr.
2015;145(8):1865e72
63. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis:
an approach to the etiology of age-related macular
degeneration. Proc Natl Acad Sci U S A. 2002;99(23):14682e7
64. Dalle-Donne I, Rossi R, Giustarini D, et al. Protein carbonyl
groups as biomarkers of oxidative stress. Clin Chim Acta.
2003;329(1-2):23e38
65. Dasch B, Fuhs A, Behrens T, et al. Inflammatory markers in
age-related maculopathy: cross-sectional analysis from the
Muenster Aging and Retina Study. Arch Ophthalmol.
2005;123(11):1501e6
66. Dashti N, McGwin G, Owsley C, Curcio CA. Plasma
apolipoproteins and risk for age related maculopathy. Br J
Ophthalmol. 2006;90(8):1028e33
67. Davari MH, Gheitasi H, Yaghobi G, Heydari B. Correlation
between serum lipids and age-related macular
degeneration: a case-control study. J Res Health Sci.
2013;13(1):98e101
68. De La Paz MA, Zhang J, Fridovich I. Red blood cell antioxidant
enzymes in age-related macular degeneration. Br J
Ophthalmol. 1996;80(5):445e50
69. Defay R, Pinchinat S, Lumbroso S, et al. Sex steroids and agerelated macular degeneration in older French women: the
POLA study. Ann Epidemiol. 2004;14(3):202e8
70. Delcourt C, Carriere I, Delage M, et al. Plasma lutein and
zeaxanthin and other carotenoids as modifiable risk factors
for age-related maculopathy and cataract: the POLA Study.
Invest Ophthalmol Vis Sci. 2006;47(6):2329e35
71. Delcourt C, Cristol JP, Leger CL, et al. Associations of
antioxidant enzymes with cataract and age-related macular
degeneration. The POLA Study. Pathologies Oculaires Liees a
l’Age. Ophthalmology. 1999;106(2):215e22
72. Delcourt C, Cristol JP, Tessier F, et al. Age-related macular
degeneration and antioxidant status in the POLA study.
POLA Study Group. Pathologies Oculaires Liees a l’Age. Arch
Ophthalmol. 1999;117(10):1384e90
73. Delcourt C, Michel F, Colvez A, et al. Associations of
cardiovascular disease and its risk factors with age-related
macular degeneration: the POLA study. Ophthalmic
Epidemiol. 2001;8(4):237e49
74. dell’Omo R, Cassetta M, dell’Omo E, et al. Aqueous
humor levels of vascular endothelial growth
factor before and after intravitreal bevacizumab in type 3
versus type 1 and 2 neovascularization.
A prospective, case-control study. Am J Ophthalmol.
2012;153(1):155e61.e2
75. Dentchev T, Milam AH, Lee VM, et al. Amyloid-beta is found
in drusen from some age-related macular degeneration
retinas, but not in drusen from normal retinas. Mol Vis.
2003;9:184e90
76. Doni A, Garlanda C, Bottazzi B, et al. Interactions of the
humoral pattern recognition molecule PTX3 with the
complement system. Immunobiology. 2012;217(11):1122e8
77. Duvvari MR, Paun CC, Buitendijk GH, et al. Analysis of rare
variants in the C3 gene in patients with age-related macular
degeneration. PLoS One. 2014;9(4):e94165
78. Ebrahem Q, Renganathan K, Sears J, et al.
Carboxyethylpyrrole oxidative protein modifications
stimulate neovascularization: Implications for age-related
macular degeneration. Proc Natl Acad Sci U S A.
2006;103(36):13480e4
79. Ebrahimi KB, Fijalkowski N, Cano M, Handa JT. Decreased
membrane complement regulators in the retinal pigmented
epithelium contributes to age-related macular degeneration.
J Pathol. 2013;229(5):729e42
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
80. Emerging Risk Factors C, Erqou S, Kaptoge S, et al.
Lipoprotein(a) concentration and the risk of coronary heart
disease, stroke, and nonvascular mortality. JAMA.
2009;302(4):412e23
81. Enders P, Muether PS, Hermann M, et al. Long-term
alterations of systemic vascular endothelial growth factor
levels in patients treated with ranibizumab for age-related
macular degeneration. Retina. 2015;35(3):454e8
82. Erie JC, Good JA, Butz JA, et al. Urinary cadmium and agerelated macular degeneration. Am J Ophthalmol.
2007;144(3):414e8
83. Ersoy L, Ristau T, Lechanteur YT, et al. Nutritional risk
factors for age-related macular degeneration. Biomed Res
Int. 2014;2014:413150
84. Ertekin S, Yildirim O, Dinc E, et al. Evaluation of circulating
miRNAs in wet age-related macular degeneration. Mol Vis.
2014;20:1057e66
85. Evereklioglu C, Doganay S, Er H, et al. Serum leptin
concentrations are decreased and correlated with disease
severity in age-related macular degeneration: a preliminary
study. Eye (Lond). 2003;17(3):350e5
86. Evereklioglu C, Er H, Doganay S, et al. Nitric oxide
and lipid peroxidation are increased and associated with
decreased antioxidant enzyme activities in patients with
age-related macular degeneration. Doc Ophthalmol.
2003;106(2):129e36
87. Eye-Disease-Case-Control-Study-Group. Antioxidant status
and neovascular age-related macular degeneration. Eye
Disease Case-Control Study Group. Arch Ophthalmol.
1993;111(1):104e9
88. Eye-Disease-Case-Control-Study-Group. Risk factors for
neovascular age-related macular degeneration. The Eye
Disease Case-Control Study Group. Arch Ophthalmol.
1992;110(12):1701e8
89. Faber C, Jehs T, Juel HB, et al. Early and exudative age-related
macular degeneration is associated with increased plasma
levels of soluble TNF receptor II. Acta Ophthalmol.
2015;93(3):242e7
90. Faber C, Singh A, Kruger Falk M, et al. Age-related macular
degeneration is associated with increased proportion of
CD56(þ) T cells in peripheral blood. Ophthalmology.
2013;120(11):2310e6
91. Falk MK, Singh A, Faber C, et al. Blood expression levels of
chemokine receptor CCR3 and chemokine CCL11 in agerelated macular degeneration: a case-control study. BMC
Ophthalmol. 2014;14:22
92. Falk MK, Singh A, Faber C, et al. CX3CL1/CX3CR1 and CCL2/
CCR2 chemokine/chemokine receptor complex in patients
with AMD. PLoS One. 2014;9(12):e112473
93. Falk MK, Singh A, Faber C, et al. Dysregulation of CXCR3
expression on peripheral blood leukocytes in patients with
neovascular age-related macular degeneration. Invest
Ophthalmol Vis Sci. 2014;55(7):4050e6
94. Fauser S, Smailhodzic D, Caramoy A, et al. Evaluation of
serum lipid concentrations and genetic variants at highdensity lipoprotein metabolism loci and TIMP3 in agerelated macular degeneration. Invest Ophthalmol Vis Sci.
2011;52(8):5525e8
95. Fiedor J, Burda K. Potential role of carotenoids as
antioxidants in human health and disease. Nutrients.
2014;6(2):466e88
96. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids
in the vertebrate retina. Prog Lipid Res. 1983;22(2):79e131
97. Fourgeux C, Dugas B, Richard F, et al. Single nucleotide
polymorphism in the cholesterol-24S-hydroxylase
(CYP46A1) gene and its association with CFH and LOC387715
gene polymorphisms in age-related macular degeneration.
Invest Ophthalmol Vis Sci. 2012;53(11):7026e33
31
98. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge. Clin
Chem. 1972;18(6):499e502
99. Fritsche LG, Chen W, Schu M, et al. Seven new loci
associated with age-related macular degeneration. Nat
Genet. 2013;45(4):433e9, 9e1-2.
100. Fritsche LG, Fariss RN, Stambolian D, et al. Age-related
macular degeneration: genetics and biology coming
together. Annu Rev Genomics Hum Genet. 2014;15:151e71
101. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide
association study of age-related macular degeneration
highlights contributions of rare and common variants. Nat
Genet. 2016;48(2):134e43
102. Gajowik A, Dobrzynska MM. Lycopene - antioxidant with
radioprotective and anticancer properties. A review. Rocz
Panstw Zakl Hig. 2014;65(4):263e71
103. Gale CR, Hall NF, Phillips DI, Martyn CN. Lutein and
zeaxanthin status and risk of age-related macular
degeneration. Invest Ophthalmol Vis Sci. 2003;44(6):2461e5
104. Garcia A, Zanibbi K. Homocysteine and cognitive function in
elderly people. CMAJ. 2004;171(8):897e904
105. Gasque P. Complement: a unique innate immune sensor for
danger signals. Mol Immunol. 2004;41(11):1089e98
106. Geerlings M, de Jong EK, den Hollander AI. The complement
system in age-related macular degeneration: a review of rare
genetic variants and implications for personalized
treatment. Immunology. 2017;84:65e76
107. Geerlings M, Kremlitzka M, Bakker B, et al. The functional
effect of rare variants in complement genes on C3b
degradation in patients with age-related macular
degeneration. JAMA Ophthalmol. 2017;135(1):39e46
108. Geyer PE, Kulak NA, Pichler G, et al. Plasma proteome
profiling to assess human health and disease. Cell Syst.
2016;2(3):185e95
109. Ghorbanihaghjo A, Javadzadeh A, Rashtchizadeh N, et al.
Osteoprotegerin and soluble receptor activator of nuclear
factor-kappa B ligand in exudative age-related macular
degeneration. Acta Med Iran. 2014;52(4):265e70
110. Ghosh S, Saha M, Das D. A study on plasma homocysteine
level in age-related macular degeneration. Nepal J
Ophthalmol. 2013;5(2):195e200
111. Golan S, Shalev V, Treister G, et al. Reconsidering the
connection between vitamin D levels and age-related
macular degeneration. Eye (Lond). 2011;25(9):1122e9
112. Goncalves FT, Cezario SM, Calastri MC, et al. Influence of
VEGF-C936T genetic variant on age-related macular
degeneration. Arq Bras Oftalmol. 2015;78(5):290e4
113. Gopinath B, Flood VM, Rochtchina E, et al. Homocysteine,
folate, vitamin B-12, and 10-y incidence of age-related
macular degeneration. Am J Clin Nutr. 2013;98(1):129e35
114. Grassmann F, Schoenberger PG, Brandl C, et al. A circulating
microrna profile is associated with late-stage neovascular
age-related macular degeneration. PLoS One.
2014;9(9):e107461
115. Grierson R, Meyer-Rusenberg B, Kunst F, et al. Endothelial
progenitor cells and plasma vascular endothelial growth
factor and stromal cell-derived factor-1 during ranibizumab
treatment for neovascular age-related macular
degeneration. J Ocul Pharmacol Ther. 2013;29(6):530e8
116. Grunin M, Burstyn-Cohen T, Hagbi-Levi S, et al. Chemokine
receptor expression in peripheral blood monocytes from
patients with neovascular age-related macular
degeneration. Invest Ophthalmol Vis Sci.
2012;53(9):5292e300
117. Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein
adducts and autoantibodies, biomarkers for age-related
macular degeneration. J Biol Chem. 2003;278(43):42027e35
32
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
118. Gu J, Pauer GJ, Yue X, et al. Assessing susceptibility to agerelated macular degeneration with proteomic and genomic
biomarkers. Mol Cell Proteomics. 2009;8(6):1338e49
119. Gurne DH, Tso MO, Edward DP, Ripps H. Antiretinal
antibodies in serum of patients with age-related macular
degeneration. Ophthalmology. 1991;98(5):602e7
120. Guymer R, Cipriani T, Rittenhouse KD, et al. Plasma levels of
amyloid beta and other proinflammatory mediators in
patients with age-related macular degeneration. Graefes
Arch Clin Exp Ophthalmol. 2015;253(8):1347e54
121. Guymer RH, Tao LW, Goh JK, et al. Identification of urinary
biomarkers for age-related macular degeneration. Invest
Ophthalmol Vis Sci. 2011;52(7):4639e44
122. Gu X, Yu X, Dai H. Intravitreal injection of ranibizumab
for treatment of age-related macular degeneration: effects
on serum VEGF concentration. Curr Eye Res.
2014;39(5):518e21
123. Haas P, Aggermann T, Nagl M, et al. Implication of CD21,
CD35, and CD55 in the pathogenesis of age-related macular
degeneration. Am J Ophthalmol. 2011;152(3):396e9.e1
124. Haas P, Kubista KE, Krugluger W, et al. Impact of visceral fat
and pro-inflammatory factors on the pathogenesis of agerelated macular degeneration. Acta Ophthalmol.
2015;93(6):533e8
125. Haas P, Steindl K, Aggermann T, et al. Serum VEGF and CFH
in exudative age-related macular degeneration. Curr Eye
Res. 2011;36(2):143e8
126. Hageman GS, Luthert PJ, Victor Chong NH, et al. An
integrated hypothesis that considers drusen as biomarkers
of immune-mediated processes at the RPE-Bruch’s
membrane interface in aging and age-related macular
degeneration. Prog Retin Eye Res. 2001;20(6):705e32
127. Hageman GS, Mullins RF. Molecular composition of drusen
as related to substructural phenotype. Mol Vis. 1999;5:28
128. Hakobyan S, Harris CL, Tortajada A, et al. Measurement of
factor H variants in plasma using variant-specific
monoclonal antibodies: application to assessing risk of agerelated macular degeneration. Invest Ophthalmol Vis Sci.
2008;49(5):1983e90
129. Hashizume K, Hirasawa M, Imamura Y, et al. Retinal
dysfunction and progressive retinal cell death in SOD1deficient mice. Am J Pathol. 2008;172(5):1325e31
130. Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the
alternative pathway of complement in humans and agerelated macular degeneration. Hum Mol Genet.
2010;19(1):209e15
131. Hegele RA. Plasma lipoproteins: genetic influences and
clinical implications. Nat Rev Genet. 2009;10(2):109e21
132. Heuberger RA, Fisher AI, Jacques PF, et al. Relation of blood
homocysteine and its nutritional determinants to agerelated maculopathy in the third National Health and
Nutrition Examination Survey. Am J Clin Nutr.
2002;76(4):897e902
133. Hogan MJ. Bruch’s membrane and disease of the macula.
Role of elastic tissue and collagen. Trans Ophthalmol Soc U
K. 1967;87:113e61
134. Hogg RE, Woodside JV, Gilchrist SE, et al. Cardiovascular
disease and hypertension are strong risk factors for
choroidal neovascularization. Ophthalmology.
2008;115(6):1046e52.e2
135. Holekamp NM, Bouck N, Volpert O. Pigment epitheliumderived factor is deficient in the vitreous of patients with
choroidal neovascularization due to age-related macular
degeneration. Am J Ophthalmol. 2002;134(2):220e7
136. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren
Campagne M. Geographic atrophy: clinical features and
potential therapeutic approaches. Ophthalmology.
2014;121(5):1079e91
137. Honarmand H. Atherosclerosis induced by chlamydophila
pneumoniae: a controversial theory. Interdiscip Perspect
Infect Dis. 2013;2013:941392
138. Hong T, Tan AG, Mitchell P, Wang JJ. A review and metaanalysis of the association between C-reactive protein and
age-related macular degeneration. Surv Ophthalmol.
2011;56(3):184e94
139. Hou HY, Liang HL, Wang YS, et al. A therapeutic strategy for
choroidal neovascularization based on recruitment of
mesenchymal stem cells to the sites of lesions. Mol Ther.
2010;18(10):1837e45
140. Houston MC. Role of mercury toxicity in hypertension,
cardiovascular disease, and stroke. J Clin Hypertens
(greenwich). 2011;13(8):621e7
141. Ho L, Witteman JC, Rohrer B, et al. Lipoprotein-associated
phospholipase A2 and risk of age-related macular
degeneration: the Rotterdam Study. Arch Ophthalmol.
2009;127(3):340e1
142. Huber M, Wachtlin J. Vitreous levels of proteins implicated
in angiogenesis are modulated in patients with retinal or
choroidal neovascularization. Ophthalmologica.
2012;228(3):188e93
143. Hwang HS, Lee SB, Jee D. Association between Blood Lead
Levels and Age-Related Macular Degeneration. PLoS One.
2015;10(8):e0134338
144. Hyman L, Schachat AP, He Q, Leske MC. Hypertension,
cardiovascular disease, and age-related macular
degeneration. Age-Related Macular Degeneration Risk
Factors Study Group. Arch Ophthalmol. 2000;118(3):351e8
145. Iannaccone A, Giorgianni F, New DD, et al. Circulating
autoantibodies in age-related macular degeneration
recognize human macular tissue antigens implicated in
autophagy, immunomodulation, and protection from
oxidative stress and apoptosis. PLoS One.
2015;10(12):e0145323
146. Ikeda K, Higashi T, Sano H, et al. N (epsilon)-(carboxymethyl)
lysine protein adduct is a major immunological epitope in
proteins modified with advanced glycation end products of
the Maillard reaction. Biochemistry. 1996;35(24):8075e83
147. Ikeda T, Obayashi H, Hasegawa G, et al. Paraoxonase gene
polymorphisms and plasma oxidized low-density
lipoprotein level as possible risk factors for exudative agerelated macular degeneration. Am J Ophthalmol.
2001;132(2):191e5
148. Ilhan N, Daglioglu MC, Ilhan O, et al. Assessment of
Neutrophil/Lymphocyte Ratio in Patients with Age-related
Macular Degeneration. Ocul Immunol Inflamm.
2015;23(4):287e90
149. Inhoffen W, Nussgens Z. Rheological studies on patients
with posterior subretinal neovascularization and exudative
age-related macular degeneration. Graefes Arch Clin Exp
Ophthalmol. 1990;228(4):316e20
150. Itty S, Day S, Lyles KW, et al. Vitamin D deficiency in
neovascular versus nonneovascular age-related macular
degeneration. Retina. 2014;34(9):1779e86
151. Jager RD, Mieler WF, Miller JW. Age-related macular
degeneration. N Engl J Med. 2008;358(24):2606e17
152. Javadzadeh A, Ghorbanihaghjo A, Bahreini E, et al. Plasma
oxidized LDL and thiol-containing molecules in patients
with exudative age-related macular degeneration. Mol Vis.
2010;16:2578e84
153. Javadzadeh A, Ghorbanihaghjo A, Bahreini E, et al. Serum
paraoxonase phenotype distribution in exudative agerelated macular degeneration and its relationship to
homocysteine and oxidized low-density lipoprotein. Retina.
2012;32(4):658e66
154. Javadzadeh A, Ghorbanihaghjo A, Rashtchizadeh N, et al.
Enhanced susceptibility of low-density lipoprotein to
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
oxidation in wet type age-related macular degeneration in
male patients. Saudi Med J. 2007;28(2):221e4
Jia L, Dong Y, Yang H, et al. Serum superoxide dismutase and
malondialdehyde levels in a group of Chinese patients with
age-related macular degeneration. Aging Clin Exp Res.
2011;23(4):264e7
Joachim SC, Bruns K, Lackner KJ, et al. Analysis of IgG
antibody patterns against retinal antigens and antibodies to
alpha-crystallin, GFAP, and alpha-enolase in sera of patients
with “wet” age-related macular degeneration. Graefes Arch
Clin Exp Ophthalmol. 2007;245(5):619e26
Joachim ND, Mitchell P, Kifley A, Wang JJ. Incidence,
progression, and associated risk factors of medium drusen
in age-related macular degeneration: findings from the 15year follow-up of an Australian cohort. JAMA Ophthalmol.
2015;133(6):698e705
Johnson LV, Anderson DH. Age-related macular
degeneration and the extracellular matrix. N Engl J Med.
2004;351(4):320e2
Johnson LV, Leitner WP, Rivest AJ, et al. The Alzheimer’s A
beta -peptide is deposited at sites of complement activation
in pathologic deposits associated with aging and age-related
macular degeneration. Proc Natl Acad Sci U S A.
2002;99(18):11830e5
Jonas JB, Nangia V, Kulkarni M, et al. Associations of early
age-related macular degeneration with ocular and general
parameters. The Central India Eyes and Medical Study. Acta
Ophthalmol. 2012;90(3):e185e91
Jonasson F, Fisher DE, Eiriksdottir G, et al. Five-year
incidence, progression, and risk factors for age-related
macular degeneration: the age, gene/environment
susceptibility study. Ophthalmology. 2014;121(9):1766e72
Juel HB, Faber C, Munthe-Fog L, et al. Systemic and Ocular
Long Pentraxin 3 in Patients with Age-Related Macular
Degeneration. PLoS One. 2015;10(7):e0132800
Junemann AG, Stopa P, Michalke B, et al. Levels of aqueous
humor trace elements in patients with non-exsudative agerelated macular degeneration: a case-control study. PLoS
One. 2013;8(2):e56734
Justilien V, Pang JJ, Renganathan K, et al. SOD2 knockdown
mouse model of early AMD. Invest Ophthalmol Vis Sci.
2007;48(10):4407e20
Kabasawa S, Mori K, Horie-Inoue K, et al. Associations of
cigarette smoking but not serum fatty acids with age-related
macular degeneration in a Japanese population.
Ophthalmology. 2011;118(6):1082e8
Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a
predictor of vascular disease. Curr Pharm Des.
2007;13(16):1647e59
Kalayoglu MV, Galvan C, Mahdi OS, et al. Serological
association between Chlamydia pneumoniae infection and
age-related macular degeneration. Arch Ophthalmol.
2003;121(4):478e82
Kamburoglu G, Gumus K, Kadayifcilar S, Eldem B. Plasma
homocysteine, vitamin B12 and folate levels in age-related
macular degeneration. Graefes Arch Clin Exp Ophthalmol.
2006;244(5):565e9
Kang GY, Bang JY, Choi AJ, et al. Exosomal proteins in the
aqueous humor as novel biomarkers in patients with
neovascular age-related macular degeneration. J Proteome
Res. 2014;13(2):581e95
Kannan R, Sreekumar PG, Hinton DR. Novel roles for alphacrystallins in retinal function and disease. Prog Retin Eye
Res. 2012;31(6):576e604
Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E.
Lipoprotein(a)eAn independent causal risk factor for
cardiovascular disease and current therapeutic options.
Atheroscler Suppl. 2015;18:263e7
33
172. Kavanagh D, Yu Y, Schramm EC, et al. Rare genetic variants
in the CFI gene are associated with advanced age-related
macular degeneration and commonly result in reduced
serum factor I levels. Hum Mol Genet. 2015;24(13):3861e70
173. Kennaway DJ, Lushington K, Dawson D, et al. Urinary 6sulfatoxymelatonin excretion and aging: new results and a
critical review of the literature. J Pineal Res.
1999;27(4):210e20
174. Kikuchi M, Nakamura M, Ishikawa K, et al. Elevated Creactive protein levels in patients with polypoidal choroidal
vasculopathy and patients with neovascular age-related
macular degeneration. Ophthalmology. 2007;114(9):1722e7
175. Kim HJ, Ahn SJ, Woo SJ, et al. Proteomics-based
identification and validation of novel plasma biomarkers
phospholipid transfer protein and mannan-binding lectin
serine protease-1 in age-related macular degeneration. Sci
Rep. 2016;6:32548
176. Kim EC, Cho E, Jee D. Association between blood cadmium
level and age-related macular degeneration in a
representative Korean population. Invest Ophthalmol Vis
Sci. 2014;55(9):5702e10
177. Kim EC, Han K, Jee D. Inverse relationship between high
blood 25-hydroxyvitamin D and late stage of age-related
macular degeneration in a representative Korean
population. Invest Ophthalmol Vis Sci. 2014;55(8):4823e31
178. Kim TW, Kang JW, Ahn J, et al. Proteomic analysis of the
aqueous humor in age-related macular degeneration (AMD)
patients. J Proteome Res. 2012;11(8):4034e43
179. Kim HJ, Woo SJ, Suh EJ, et al. Identification of vinculin as a
potential plasma marker for age-related macular
degeneration. Invest Ophthalmol Vis Sci.
2014;55(11):7166e76
180. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of
age-related macular degeneration and associated risk
factors. Arch Ophthalmol. 2010;128(6):750e8
181. Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its
risk factors and treatment, and age-related macular
degeneration: Women’s Health Initiative Sight Exam
ancillary study. Am J Ophthalmol. 2007;143(3):473e83
182. Klein R, Klein BE, Franke T. The relationship of
cardiovascular disease and its risk factors to age-related
maculopathy. The Beaver Dam Eye Study. Ophthalmology.
1993;100(3):406e14
183. Klein R, Klein BE, Knudtson MD, et al. Systemic markers of
inflammation, endothelial dysfunction, and age-related
maculopathy. Am J Ophthalmol. 2005;140(1):35e44
184. Klein R, Klein BE, Knudtson MD, et al. Subclinical
atherosclerotic cardiovascular disease and early age-related
macular degeneration in a multiracial cohort: the
Multiethnic Study of Atherosclerosis. Arch Ophthalmol.
2007;125(4):534e43
185. Klein R, Klein BE, Marino EK, et al. Early age-related
maculopathy in the cardiovascular health study.
Ophthalmology. 2003;110(1):25e33
186. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The
association of cardiovascular disease with the long-term
incidence of age-related maculopathy: the Beaver Dam Eye
Study. Ophthalmology. 2003;110(6):1273e80
187. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. Association
of emphysema, gout, and inflammatory markers with longterm incidence of age-related maculopathy. Arch
Ophthalmol. 2003;121(5):674e8
188. Klein R, Knudtson MD, Klein BE, et al. Inflammation,
complement factor h, and age-related macular
degeneration: the Multi-ethnic Study of Atherosclerosis.
Ophthalmology. 2008;115(10):1742e9
189. Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C
level, kidney disease markers, and incidence of age-related
34
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
macular degeneration: the Beaver Dam Eye Study. Arch
Ophthalmol. 2009;127(2):193e9
Klein R, Myers CE, Buitendijk GH, et al. Lipids, lipid genes,
and incident age-related macular degeneration: the three
continent age-related macular degeneration consortium.
Am J Ophthalmol. 2014;158(3):513e24.e3
Klein R, Myers CE, Cruickshanks KJ, et al. Markers of
inflammation, oxidative stress, and endothelial dysfunction
and the 20-year cumulative incidence of early age-related
macular degeneration: the Beaver Dam Eye Study. JAMA
Ophthalmol. 2014;132(4):446e55
Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of
age-related macular degeneration. Am J Ophthalmol.
2004;137(3):486e95
Klein RJ, Zeiss C, Chew EY, et al. Complement factor H
polymorphism in age-related macular degeneration.
Science. 2005;308(5720):385e9
Koss MJ, Hoffmann J, Nguyen N, et al. Proteomics of vitreous
humor of patients with exudative age-related macular
degeneration. PLoS One. 2014;9(5):e96895
Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of
the protective role of lutein and zeaxanthin in the eye. Annu
Rev Nutr. 2003;23:171e201
Kubicka-Trzaska A, Wilanska J, Romanowska-Dixon B,
Sanak M. Circulating antiretinal antibodies predict the
outcome of anti-VEGF therapy in patients with exudative
age-related macular degeneration. Acta Ophthalmol.
2012;90(1):e21e4
Kubicka-Trzaska A, Wilanska J, Romanowska-Dixon B,
Sanak M. Circulating anti-retinal antibodies in response
to anti-angiogenic therapy in exudative age-related
macular degeneration. Acta Ophthalmol.
2014;92(8):e610e4
La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm
shift towards personalized cancer medicine. Nat Rev Clin
Oncol. 2011;8(10):587e96
La TY, Cho E, Kim EC, et al. Prevalence and risk factors for
age-related macular degeneration: Korean National Health
and Nutrition Examination Survey 2008-2011. Curr Eye Res.
2014;39(12):1232e9
Lad EM, Cousins SW, Van Arnam JS, Proia AD. Abundance
of infiltrating CD163þ cells in the retina of postmortem
eyes with dry and neovascular age-related macular
degeneration. Graefes Arch Clin Exp Ophthalmol.
2015;253(11):1941e5
Lee H, Choi AJ, Kang GY, et al. Increased 26S proteasome
non-ATPase regulatory subunit 1 in the aqueous humor of
patients with age-related macular degeneration. BMB Rep.
2014;47(5):292e7
Levitt DG, Levitt MD. Human serum albumin homeostasis: a
new look at the roles of synthesis, catabolism, renal and
gastrointestinal excretion, and the clinical value of serum
albumin measurements. Int J Gen Med. 2016;9:229e55
Liew G, Mitchell P, Wong TY, et al. CKD increases the risk of
age-related macular degeneration. J Am Soc Nephrol.
2008;19(4):806e11
Lim LS, Mitchell P, Seddon JM, et al. Age-related macular
degeneration. Lancet. 2012;379(9827):1728e38
Lip PL, Blann AD, Hope-Ross M, et al. Age-related macular
degeneration is associated with increased vascular
endothelial growth factor, hemorheology and endothelial
dysfunction. Ophthalmology. 2001;108(4):705e10
Lorenzo Y, Azqueta A, Luna L, et al. The carotenoid betacryptoxanthin stimulates the repair of DNA oxidation
damage in addition to acting as an antioxidant in human
cells. Carcinogenesis. 2009;30(2):308e14
Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233e41
208. Lusis AJ, Pajukanta P. A treasure trove for lipoprotein
biology. Nat Genet. 2008;40(2):129e30
209. Lyngholm M, Vorum H, Nielsen K, et al. Attempting to
distinguish between endogenous and contaminating
cytokeratins in a corneal proteomic study. BMC Ophthalmol.
2011;11:3
210. Machalinska A, Klos P, Safranow K, et al. Neural stem/
progenitor cells circulating in peripheral blood of patients
with neovascular form of AMD: a novel view on
pathophysiology. Graefes Arch Clin Exp Ophthalmol.
2011;249(12):1785e94
211. Machalinska A, Safranow K, Dziedziejko V, et al. Different
populations of circulating endothelial cells in patients with
age-related macular degeneration: a novel insight into
pathogenesis. Invest Ophthalmol Vis Sci. 2011;52(1):93e100
212. Maninger N, Wolkowitz OM, Reus VI, et al. Neurobiological
and neuropsychiatric effects of dehydroepiandrosterone
(DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol.
2009;30(1):65e91
213. Manresa N, Mulero J, Losada M, Zafrilla P. Effect of
Pegaptanib and Ranibizumab on Plasma and Vitreous
Homocysteine in Patients with Exudative Age-Related
Macular Degeneration. Retina. 2015;35(9):1765e71
214. Mares-Perlman JA, Brady WE, Klein R, et al. Serum
antioxidants and age-related macular degeneration in a
population-based case-control study. Arch Ophthalmol.
1995;113(12):1518e23
215. Mauer J, Denson JL, Bruning JC. Versatile functions for IL-6 in
metabolism and cancer. Trends Immunol. 2015;36(2):92e101
216. Mayer MJ, van Kuijk FJ, Ward B, Glucs A. Whole blood
selenium in exudative age-related maculopathy. Acta
Ophthalmol Scand. 1998;76(1):62e7
217. McGwin G, Hall TA, Xie A, Owsley C. The relation between C
reactive protein and age related macular degeneration in the
Cardiovascular Health Study. Br J Ophthalmol.
2005;89(9):1166e70
218. Meister A. Glutathione metabolism and its selective
modification. J Biol Chem. 1988;263(33):17205e8
219. Merle BM, Benlian P, Puche N, et al. Circulating omega-3
Fatty acids and neovascular age-related macular
degeneration. Invest Ophthalmol Vis Sci. 2014;55(3):2010e9
220. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT.
Complement System Part I - Molecular Mechanisms of
Activation and Regulation. Front Immunol. 2015;6:262
221. Merle BM, Delyfer MN, Korobelnik JF, et al. High
concentrations of plasma n3 fatty acids are associated with
decreased risk for late age-related macular degeneration.
J Nutr. 2013;143(4):505e11
222. Merle BM, Richard F, Benlian P, et al. CFH Y402H and ARMS2
A69S Polymorphisms and Oral Supplementation with
Docosahexaenoic Acid in Neovascular Age-Related Macular
Degeneration Patients: The NAT2 Study. PLoS One.
2015;10(7):e0130816
223. Michalska-Malecka K, Slowinska L, Dorecka M,
Romaniuk W. Correlations in some pathogenetic factors and
values of hemorheological parameters in age-related
macular degeneration. Clin Hemorheol Microcirc.
2008;38(3):209e16
224. Michikawa T, Ishida S, Nishiwaki Y, et al. Serum
antioxidants and age-related macular degeneration among
older Japanese. Asia Pac J Clin Nutr. 2009;18(1):1e7
225. Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor
system and its role in physiological and pathological
conditions. Clin Sci (lond). 2012;122(4):143e59
226. Millen AE, Voland R, Sondel SA, et al. Vitamin D status and
early age-related macular degeneration in postmenopausal
women. Arch Ophthalmol. 2011;129(4):481e9
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
227. Miller DM, Espinosa-Heidmann DG, Legra J, et al. The
association of prior cytomegalovirus infection with
neovascular age-related macular degeneration. Am J
Ophthalmol. 2004;138(3):323e8
228. Min JK, Kim J, Woo JM. Elevated Plasma
Pentraxin3 Levels and Its Association with Neovascular
Age-related Macular Degeneration. Ocul Immunol Inflamm.
2015;23(3):205e11
229. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating
microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A. 2008;105(30):10513e8
230. Mitta VP, Christen WG, Glynn RJ, et al. C-reactive protein and
the incidence of macular degeneration: pooled analysis of 5
cohorts. JAMA Ophthalmol. 2013;131(4):507e13
231. Mo FM, Proia AD, Johnson WH, et al. Interferon gammainducible protein-10 (IP-10) and eotaxin as biomarkers in
age-related macular degeneration. Invest Ophthalmol Vis
Sci. 2010;51(8):4226e36
232. Morohoshi K, Ohbayashi M, Patel N, et al. Identification of
anti-retinal antibodies in patients with age-related macular
degeneration. Exp Mol Pathol. 2012;93(2):193e9
233. Morohoshi K, Patel N, Ohbayashi M, et al. Serum
autoantibody biomarkers for age-related macular
degeneration and possible regulators of neovascularization.
Exp Mol Pathol. 2012;92(1):64e73
234. Morrison MA, Silveira AC, Huynh N, et al. Systems biologybased analysis implicates a novel role for vitamin D
metabolism in the pathogenesis of age-related macular
degeneration. Hum Genomics. 2011;5(6):538e68
235. Munch IC, Linneberg A, Larsen M. Precursors of age-related
macular degeneration: associations with physical activity,
obesity, and serum lipids in the inter99 eye study. Invest
Ophthalmol Vis Sci. 2013;54(6):3932e40
236. Nagase H, Visse R, Murphy G. Structure and function of
matrix metalloproteinases and TIMPs. Cardiovasc Res.
2006;69(3):562e73
237. Nan R, Farabella I, Schumacher FF, et al. Zinc binding to the
Tyr402 and His402 allotypes of complement factor H:
possible implications for age-related macular degeneration.
J Mol Biol. 2011;408(4):714e35
238. Nan R, Gor J, Lengyel I, Perkins SJ. Uncontrolled zinc- and
copper-induced oligomerisation of the human complement
regulator factor H and its possible implications for function
and disease. J Mol Biol. 2008;384(5):1341e52
239. Nan R, Tetchner S, Rodriguez E, et al. Zinc-induced selfassociation of complement C3b and Factor H: implications
for inflammation and age-related macular degeneration.
J Biol Chem. 2013;288(26):19197e210
240. Nassar K, Grisanti S, Elfar E, et al. Serum cytokines as
biomarkers for age-related macular degeneration. Graefes
Arch Clin Exp Ophthalmol. 2015;253(5):699e704
241. Nita M, Strzalka-Mrozik B, Grzybowski A, et al. Age-related
macular degeneration and changes in the extracellular
matrix. Med Sci Monit. 2014;20:1003e16
242. Ni J, Yuan X, Gu J, et al. Plasma protein pentosidine
and carboxymethyllysine, biomarkers for age-related
macular degeneration. Mol Cell Proteomics.
2009;8(8):1921e33
243. Nobl M, Reich M, Dacheva I, et al. Proteomics of vitreous in
neovascular age-related macular degeneration. Exp Eye Res.
2016;146:107e17
244. Norman AW. From vitamin D to hormone D: fundamentals
of the vitamin D endocrine system essential for good health.
Am J Clin Nutr. 2008;88(2):491Se9S
245. Nowak JZ. Oxidative stress, polyunsaturated fatty acidsderived oxidation products and bisretinoids as potential
inducers of CNS diseases: focus on age-related macular
degeneration. Pharmacol Rep. 2013;65(2):288e304
35
246. Nowak M, Swietochowska E, Marek B, et al. Changes in lipid
metabolism in women with age-related macular
degeneration. Clin Exp Med. 2005;4(4):183e7
247. Obeid R, Ninios K, Loew U, et al. Aqueous humor glycation
marker and plasma homocysteine in macular degeneration.
Clin Chem Lab Med. 2013;51(3):657e63
248. Okamoto T, Tanaka S, Stan AC, et al. Advanced glycation
end products induce angiogenesis in vivo. Microvasc Res.
2002;63(2):186e95
249. Oliver VF, Franchina M, Jaffe AE, et al. Hypomethylation of
the IL17RC promoter in peripheral blood leukocytes is not a
hallmark of age-related macular degeneration. Cell Rep.
2013;5(6):1527e35
250. Oliver VF, Jaffe AE, Song J, et al. Differential DNA
methylation identified in the blood and retina of AMD
patients. Epigenetics. 2015;10(8):698e707
251. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors
for lung cancer and for intervention effects in CARET, the
Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst.
1996;88(21):1550e9
252. Orban T, Johnson WM, Dong Z, et al. Serum levels of lipid
metabolites in age-related macular degeneration. FASEB J.
2015;29(11):4579e88
253. Osborn MP, Park Y, Parks MB, et al. Metabolome-wide
association study of neovascular age-related macular
degeneration. PLoS One. 2013;8(8):e72737
254. Ouchi M, Ikeda T, Nakamura K, et al. A novel relation of fatty
acid with age-related macular degeneration.
Ophthalmologica. 2002;216(5):363e7
255. Ouweneel AB, Van Eck M. Lipoproteins as modulators of
atherothrombosis: from endothelial function to primary and
secondary coagulation. Vascul Pharmacol. 2016;82:1e10
256. Owen LA, Morrison MA, Ahn J, et al. FLT1 genetic variation
predisposes to neovascular AMD in ethnically diverse
populations and alters systemic FLT1 expression. Invest
Ophthalmol Vis Sci. 2014;55(6):3543e54
257. Ozkan B, Karabas LV, Altintas O, et al. Plasma
antiphospholipid antibody levels in age-related macular
degeneration. Can J Ophthalmol. 2012;47(3):264e8
258. Packer L, Weber SU, Rimbach G. Molecular aspects of alphatocotrienol antioxidant action and cell signalling. J Nutr.
2001;131(2):369Se73S
259. Parekh N, Chappell RJ, Millen AE, et al. Association between
vitamin D and age-related macular degeneration in the
Third National Health and Nutrition Examination Survey,
1988 through 1994. Arch Ophthalmol. 2007;125(5):661e9
260. Park KH, Choi AJ, Yoon J, et al. Wnt modulators in the
aqueous humor are associated with outer retinal damage
severity in patients with neovascular age-related macular
degeneration. Invest Ophthalmol Vis Sci. 2014;55(9):5522e30
261. Park SJ, Lee JH, Woo SJ, et al. Age-related macular
degeneration: prevalence and risk factors from Korean
National Health and Nutrition Examination Survey, 2008
through 2011. Ophthalmology. 2014;121(9):1756e65
262. Park SJ, Lee JH, Woo SJ, et al. Five heavy metallic elements
and age-related macular degeneration: Korean National
Health and Nutrition Examination Survey, 2008-2011.
Ophthalmology. 2015;122(1):129e37
263. Park DH, Shin JP, Kim IT. Association of plasma
malondialdehyde with ARMS2 genetic variants and
phenotypes in polypoidal choroidal vasculopathy and agerelated macular degeneration. Retina. 2014;34(6):1167e76
264. Patel N, Ohbayashi M, Nugent AK, et al. Circulating antiretinal antibodies as immune markers in age-related
macular degeneration. Immunology. 2005;115(3):422e30
265. Paun CC, Ersoy L, Schick T, et al. Genetic variants and
systemic complement activation levels are associated with
serum lipoprotein levels in age-related macular
36
266.
267.
268.
269.
270.
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
degeneration. Invest Ophthalmol Vis Sci.
2015;56(13):7766e73
Paun CC, Lechanteur YT, Groenewoud JM, et al. A Novel
Complotype Combination Associates with Age-Related
Macular Degeneration and High Complement Activation
Levels in vivo. Sci Rep. 2016;6:26568
Peiretti E, Mandas A, Abete C, et al. Age-related macular
degeneration and cognitive impairment show similarities in
changes of neutral lipids in peripheral blood mononuclear
cells. Exp Eye Res. 2014;124:11e6
Penfold PL, Provis JM, Furby JH, et al. Autoantibodies to
retinal astrocytes associated with age-related macular
degeneration. Graefes Arch Clin Exp Ophthalmol.
1990;228(3):270e4
Plestina-Borjan I, Katusic D, Medvidovic-Grubisic M, et al.
Association of age-related macular degeneration with
erythrocyte antioxidant enzymes activity and serum total
antioxidant status. Oxid Med Cell Longev. 2015;2015:804054
Podrez EA, Poliakov E, Shen Z, et al. A novel family of
atherogenic oxidized phospholipids promotes macrophage
foam cell formation via the scavenger receptor CD36 and is
enriched in atherosclerotic lesions. J Biol Chem.
2002;277(41):38517e23
Poletaev AB, Churilov LP, Stroev YI, Agapov MM.
Immunophysiology versus immunopathology: natural
autoimmunity in human health and disease.
Pathophysiology. 2012;19(3):221e31
Prashar S, Pandav SS, Gupta A, Nath R. Antioxidant enzymes
in RBCs as a biological index of age related macular
degeneration. Acta Ophthalmol (copenh). 1993;71(2):214e8
Qin L, Mroczkowska SA, Ekart A, et al. Patients with early
age-related macular degeneration exhibit signs of macroand micro-vascular disease and abnormal blood glutathione
levels. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):23e30
Raghavan S, Subramaniyam G, Shanmugam N.
Proinflammatory effects of malondialdehyde in
lymphocytes. J Leukoc Biol. 2012;92(5):1055e67
Ratnapriya R, Zhan X, Fariss RN, et al. Rare and common
variants in extracellular matrix gene Fibrillin 2 (FBN2) are
associated with macular degeneration. Hum Mol Genet.
2014;23(21):5827e37
Reiter RJ, Tan DX, Mayo JC, et al. Melatonin as an
antioxidant: biochemical mechanisms and
pathophysiological implications in humans. Acta Biochim
Pol. 2003;50(4):1129e46
Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in
the reduction of oxidative stress. A review. J Biomed Sci.
2000;7(6):444e58
Reynolds R, Hartnett ME, Atkinson JP, et al. Plasma
complement components and activation fragments:
associations with age-related macular degeneration
genotypes and phenotypes. Invest Ophthalmol Vis Sci.
2009;50(12):5818e27
Reynolds R, Rosner B, Seddon JM. Serum lipid biomarkers
and hepatic lipase gene associations with age-related
macular degeneration. Ophthalmology.
2010;117(10):1989e95
Ristau T, Ersoy L, Lechanteur Y, et al. Allergy is a protective
factor against age-related macular degeneration. Invest
Ophthalmol Vis Sci. 2014;55(1):210e4
Ristau T, Paun C, Ersoy L, et al. Impact of the common
genetic associations of age-related macular degeneration
upon systemic complement component C3d levels. PLoS
One. 2014;9(3):e93459
Robman L, Baird PN, Dimitrov PN, et al. C-reactive protein
levels and complement factor H polymorphism interaction
in age-related macular degeneration and its progression.
Ophthalmology. 2010;117(10):1982e8
283. Robman L, Mahdi OS, Wang JJ, et al. Exposure to Chlamydia
pneumoniae infection and age-related macular
degeneration: the Blue Mountains Eye Study. Invest
Ophthalmol Vis Sci. 2007;48(9):4007e11
284. Rochtchina E, Wang JJ, Flood VM, Mitchell P.
Elevated serum homocysteine, low serum
vitamin B12, folate, and age-related macular degeneration:
the Blue Mountains Eye Study. Am J Ophthalmol.
2007;143(2):344e6
285. Roh MI, Kim JH, Byeon SH, et al. Estimated prevalence and
risk factor for age-related maculopathy. Yonsei Med J.
2008;49(6):931e41
286. Rosen R, Hu DN, Perez V, et al. Urinary 6-sulfatoxymelatonin
level in age-related macular degeneration patients. Mol Vis.
2009;15:1673e9
287. Ross RJ, Zhou M, Shen D, et al. Immunological protein
expression profile in Ccl2/Cx3cr1 deficient mice with lesions
similar to age-related macular degeneration. Exp Eye Res.
2008;86(4):675e83
288. Rudnicka AR, MacCallum PK, Whitelocke R, Meade TW.
Circulating markers of arterial thrombosis and late-stage
age-related macular degeneration: a case-control study. Eye
(Lond). 2010;24(7):1199e206
289. Sadler JE. Biochemistry and genetics of von Willebrand
factor. Annu Rev Biochem. 1998;67:395e424
290. Sakurada Y, Nakamura Y, Yoneyama S, et al. Aqueous
humor cytokine levels in patients with polypoidal choroidal
vasculopathy and neovascular age-related macular
degeneration. Ophthalmic Res. 2015;53(1):2e7
291. Samiec PS, Drews-Botsch C, Flagg EW, et al. Glutathione in
human plasma: decline in association with aging, agerelated macular degeneration, and diabetes. Free Radic Biol
Med. 1998;24(5):699e704
292. Sanders TA, Haines AP, Wormald R, et al. Essential fatty
acids, plasma cholesterol, and fat-soluble vitamins in
subjects with age-related maculopathy and matched control
subjects. Am J Clin Nutr. 1993;57(3):428e33
293. Satarug S, Kikuchi M, Wisedpanichkij R, et al. Prevention of
cadmium accumulation in retinal pigment epithelium with
manganese and zinc. Exp Eye Res. 2008;87(6):587e93
294. Schalinske KL, Smazal AL. Homocysteine imbalance: a
pathological metabolic marker. Adv Nutr. 2012;3(6):755e62
295. Schaumberg DA, Christen WG, Buring JE, et al. Highsensitivity C-reactive protein, other markers of
inflammation, and the incidence of macular degeneration in
women. Arch Ophthalmol. 2007;125(3):300e5
296. Schmid-Kubista KE, Glittenberg CG, Cezanne M, et al.
Daytime levels of melatonin in patients with age-related
macular degeneration. Acta Ophthalmol. 2009;87(1):89e93
297. Schoenborn JR, Wilson CB. Regulation of interferon-gamma
during innate and adaptive immune responses. Adv
Immunol. 2007;96:41e101
298. Scholl HP, Charbel Issa P, Walier M, et al. Systemic
complement activation in age-related macular
degeneration. PLoS One. 2008;3(7):e2593
299. Scotti F, Maestroni A, Palini A, et al. Endothelial progenitor
cells and response to ranibizumab in age-related macular
degeneration. Retina. 2014;34(9):1802e10
300. Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of
plasma homocysteine and risk of age-related
macular degeneration. Am J Ophthalmol. 2006;141(1):201e3
301. Seddon JM, Gensler G, Milton RC, et al. Association between
C-reactive protein and age-related macular degeneration.
JAMA. 2004;291(6):704e10
302. Seddon JM, Gensler G, Rosner B. C-reactive protein and CFH,
ARMS2/HTRA1 gene variants are independently associated
with risk of macular degeneration. Ophthalmology.
2010;117(8):1560e6
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
303. Seddon JM, George S, Rosner B, Rifai N. Progression of agerelated macular degeneration: prospective assessment of Creactive protein, interleukin 6, and other cardiovascular
biomarkers. Arch Ophthalmol. 2005;123(6):774e82
304. Semba RD, Cotch MF, Gudnason V, et al. Serum
carboxymethyllysine, an advanced glycation end product,
and age-related macular degeneration: the Age, Gene/
Environment Susceptibility-Reykjavik Study. JAMA
Ophthalmol. 2014;132(4):464e70
305. Sennlaub F, Auvynet C, Calippe B, et al. CCR2(þ) monocytes
infiltrate atrophic lesions in age-related macular disease and
mediate photoreceptor degeneration in experimental
subretinal inflammation in Cx3cr1 deficient mice. EMBO Mol
Med. 2013;5(11):1775e93
306. Seshasai S, Liao J, Toh QC, et al. Serum leptin and agerelated macular degeneration. Invest Ophthalmol Vis Sci.
2015;56(3):1880e6
307. Shankar A, Mitchell P, Rochtchina E, et al. Association
between circulating white blood cell count and long-term
incidence of age-related macular degeneration: the Blue
Mountains Eye Study. Am J Epidemiol. 2007;165(4):375e82
308. Sharma NK, Gupta A, Prabhakar S, et al. Association
between CFH Y402H polymorphism and age related macular
degeneration in North Indian cohort. PLoS One.
2013;8(7):e70193
309. Sharma NK, Prabhakar S, Gupta A, et al. New biomarker for
neovascular age-related macular degeneration: eotaxin-2.
DNA Cell Biol. 2012;31(11):1618e27
310. Sharma NK, Sharma SK, Gupta A, et al. Predictive model for
earlier diagnosis of suspected age-related macular
degeneration patients. DNA Cell Biol. 2013;32(9):549e55
311. Shen XL, Jia JH, Zhao P, et al. Changes in blood oxidative and
antioxidant parameters in a group of Chinese patients with
age-related macular degeneration. J Nutr Health Aging.
2012;16(3):201e4
312. Silva AS, Teixeira AG, Bavia L, et al. Plasma levels of
complement proteins from the alternative pathway in
patients with age-related macular degeneration are
independent of Complement Factor H Tyr(4)(0)(2)His
polymorphism. Mol Vis. 2012;18:2288e99
313. Simonelli F, Zarrilli F, Mazzeo S, et al. Serum oxidative and
antioxidant parameters in a group of Italian patients with
age-related maculopathy. Clin Chim Acta. 2002;320(1-2):111e5
314. Singh A, Faber C, Falk M, et al. Altered expression of CD46
and CD59 on leukocytes in neovascular age-related macular
degeneration. Am J Ophthalmol. 2012;154(1):193e9.e2
315. Singh A, Falk MK, Hviid TV, Sorensen TL. Increased
expression of CD200 on circulating CD11bþ monocytes in
patients with neovascular age-related macular
degeneration. Ophthalmology. 2013;120(5):1029e37
316. Singh A, Falk MK, Subhi Y, Sorensen TL. The association
between plasma 25-hydroxyvitamin D and subgroups in
age-related macular degeneration: a cross-sectional study.
PLoS One. 2013;8(7):e70948
317. Sivaprasad S, Adewoyin T, Bailey TA, et al. Estimation of
systemic complement C3 activity in age-related macular
degeneration. Arch Ophthalmol. 2007;125(4):515e9
318. Sivaprasad S, Chong NV, Bailey TA. Serum elastin-derived
peptides in age-related macular degeneration. Invest
Ophthalmol Vis Sci. 2005;46(9):3046e51
319. Smailhodzic D, Klaver CC, Klevering BJ, et al. Risk alleles in
CFH and ARMS2 are independently associated with systemic
complement activation in age-related macular
degeneration. Ophthalmology. 2012;119(2):339e46
320. Smailhodzic D, van Asten F, Blom AM, et al. Zinc
supplementation inhibits complement activation in agerelated macular degeneration. PLoS One. 2014;9(11):e112682
37
321. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen
levels, other cardiovascular risk factors, and age-related
maculopathy: the Blue Mountains Eye Study. Arch
Ophthalmol. 1998;116(5):583e7
322. Smith W, Mitchell P, Rochester C. Serum beta carotene,
alpha tocopherol, and age-related maculopathy: the Blue
Mountains Eye Study. Am J Ophthalmol. 1997;124(6):838e40
323. Song D, Dunaief JL. Retinal iron homeostasis in health and
disease. Front Aging Neurosci. 2013;5:24
324. Souied EH, Aslam T, Garcia-Layana A, et al. Omega-3 Fatty
Acids and Age-Related Macular Degeneration. Ophthalmic
Res. 2015;55(2):62e9
325. Stahl W, Sies H. Antioxidant activity of carotenoids. Mol
Aspects Med. 2003;24(6):345e51
326. Stanton CM, Yates JR, den Hollander AI, et al. Complement
factor D in age-related macular degeneration. Invest
Ophthalmol Vis Sci. 2011;52(12):8828e34
327. Subramani S, Khor SE, Livingstone BI, Kulkarni UV. Serum
uric acid levels and its association with age-related macular
degeneration (ARMD). Med J Malaysia. 2010;65(1):36e40
328. Szemraj M, Bielecka-Kowalska A, Oszajca K, et al. Serum
MicroRNAs as Potential Biomarkers of AMD. Med Sci Monit.
2015;21:2734e42
329. Takeda A, Baffi JZ, Kleinman ME, et al. CCR3 is a target for
age-related macular degeneration diagnosis and therapy.
Nature. 2009;460(7252):225e30
330. Tamer C, Oksuz H, Sogut S. Serum dehydroepiandrosterone
sulphate level in age-related macular degeneration. Am J
Ophthalmol. 2007;143(2):212e6
331. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk
factors and the long-term incidence of age-related macular
degeneration: the Blue Mountains Eye Study.
Ophthalmology. 2007;114(6):1143e50
332. Tan JS, Wang JJ, Flood V, et al. Dietary antioxidants and the
long-term incidence of age-related macular degeneration:
the Blue Mountains Eye Study. Ophthalmology.
2008;115(2):334e41
333. Tokarz P, Kaarniranta K, Blasiak J. Role of antioxidant
enzymes and small molecular weight antioxidants in the
pathogenesis of age-related macular degeneration (AMD).
Biogerontology. 2013;14(5):461e82
334. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of
vascular endothelial growth factor and pigment epitheliumderived factor in polypoidal choroidal vasculopathy and
choroidal neovascularization. Am J Ophthalmol.
2006;141(3):456e62
335. Totan Y, Cekic O, Borazan M, et al. Plasma malondialdehyde
and nitric oxide levels in age related macular degeneration.
Br J Ophthalmol. 2001;85(12):1426e8
336. Totan Y, Yagci R, Bardak Y, et al. Oxidative macromolecular
damage in age-related macular degeneration. Curr Eye Res.
2009;34(12):1089e93
337. Triebwasser MP, Roberson ED, Yu Y, et al. Rare Variants in
the Functional Domains of Complement Factor H Are
Associated With Age-Related Macular Degeneration. Invest
Ophthalmol Vis Sci. 2015;56(11):6873e8
338. Tsai DC, Charng MJ, Lee FL, et al. Different plasma levels of
vascular endothelial growth factor and nitric oxide between
patients with choroidal and retinal neovascularization.
Ophthalmologica. 2006;220(4):246e51
339. Tsang NC, Penfold PL, Snitch PJ, Billson F. Serum levels of
antioxidants and age-related macular degeneration. Doc
Ophthalmol. 1992;81(4):387e400
340. Uehara H, Mamalis C, McFadden M, et al. The reduction of
serum soluble Flt-1 in patients with neovascular age-related
macular degeneration. Am J Ophthalmol.
2015;159(1):92e100.e1-2
38
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
341. Ugurlu N, Asik MD, Yulek F, et al. Oxidative stress and antioxidative defence in patients with age-related macular
degeneration. Curr Eye Res. 2013;38(4):497e502
342. Ulas F, Balbaba M, Ozmen S, et al. Association of
dehydroepiandrosterone sulfate, serum lipids, C-reactive
protein and body mass index with age-related macular
degeneration. Int Ophthalmol. 2013;33(5):485e91
343. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant
in the CFI gene confers a high risk of age-related macular
degeneration. Nat Genet. 2013;45(7):813e7
344. van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary
intake of antioxidants and risk of age-related macular
degeneration. JAMA. 2005;294(24):3101e7
345. van Leeuwen R, Klaver CC, Vingerling JR, et al. Cholesterol
and age-related macular degeneration: is there a link? Am J
Ophthalmol. 2004;137(4):750e2
346. Venza I, Visalli M, Oteri R, et al. Combined effects of cigarette
smoking and alcohol consumption on antioxidant/oxidant
balance in age-related macular degeneration. Aging Clin Exp
Res. 2012;24(5):530e6
347. Vine AK, Stader J, Branham K, et al. Biomarkers of
cardiovascular disease as risk factors for age-related
macular degeneration. Ophthalmology.
2005;112(12):2076e80
348. Wagenseil JE, Mecham RP. New insights into elastic fiber
assembly. Birth Defects Res C Embryo Today.
2007;81(4):229e40
349. Wagner EK, Raychaudhuri S, Villalonga MB, et al. Mapping
rare, deleterious mutations in Factor H: Association with
early onset, drusen burden, and lower antigenic levels in
familial AMD. Sci Rep. 2016;6:31531
350. Wang L, Clark ME, Crossman DK, et al. Abundant lipid and
protein components of drusen. PLoS One. 2010;5(4):e10329
351. Wang H, Guo J, West XZ, et al. Detection and biological
activities of carboxyethylpyrrole ethanolamine
phospholipids (CEP-EPs). Chem Res Toxicol.
2014;27(12):2015e22
352. Wang JJ, Ross RJ, Tuo J, et al. The LOC387715 polymorphism,
inflammatory markers, smoking, and age-related macular
degeneration. A population-based case-control study.
Ophthalmology. 2008;115(4):693e9
353. Wang X, Sawada T, Sawada O, et al. Serum and plasma
vascular endothelial growth factor concentrations before
and after intravitreal injection of aflibercept or ranibizumab
for age-related macular degeneration. Am J Ophthalmol.
2014;158(4):738e44.e1
354. Wang S, Xu L, Jonas JB, et al. Dyslipidemia and eye diseases
in the adult Chinese population: the Beijing eye study. PLoS
One. 2012;7(3):e26871
355. Wei L, Liu B, Tuo J, et al. Hypomethylation of the IL17RC
promoter associates with age-related macular degeneration.
Cell Rep. 2012;2(5):1151e8
356. Weiner DE, Tighiouart H, Reynolds R, Seddon JM. Kidney
function, albuminuria and age-related macular
degeneration in NHANES III. Nephrol Dial Transplant.
2011;26(10):3159e65
357. Weismann D, Binder CJ. The innate immune response to
products of phospholipid peroxidation. Biochim Biophys
Acta. 2012;1818(10):2465e75
358. Weismann D, Hartvigsen K, Lauer N, et al. Complement
factor H binds malondialdehyde epitopes and protects from
oxidative stress. Nature. 2011;478(7367):76e81
359. West XZ, Malinin NL, Merkulova AA, et al. Oxidative stress
induces angiogenesis by activating TLR2 with novel
endogenous ligands. Nature. 2010;467(7318):972e6
360. West S, Vitale S, Hallfrisch J, et al. Are antioxidants or
supplements protective for age-related macular
degeneration? Arch Ophthalmol. 1994;112(2):222e7
361. Wills NK, Ramanujam VM, Chang J, et al. Cadmium
accumulation in the human retina: effects of age, gender,
and cellular toxicity. Exp Eye Res. 2008;86(1):41e51
362. Wills NK, Ramanujam VM, Kalariya N, et al. Copper and
zinc distribution in the human retina: relationship to
cadmium accumulation, age, and gender. Exp Eye Res.
2008;87(2):80e8
363. Wong TY, Chakravarthy U, Klein R, et al. The natural history
and prognosis of neovascular age-related macular
degeneration: a systematic review of the literature and
meta-analysis. Ophthalmology. 2008;115(1):116e26
364. Wong WL, Su X, Li X, et al. Global prevalence of age-related
macular degeneration and disease burden projection for
2020 and 2040: a systematic review and meta-analysis.
Lancet Glob Health. 2014;2(2):e106e16
365. Wu J, Cho E, Willett WC, et al. Intakes of Lutein, Zeaxanthin,
and other Carotenoids and Age-Related Macular
Degeneration during 2 decades of prospective follow-up.
JAMA Ophthalmol. 2015;133(12):1415e24
366. Wu EW, Schaumberg DA, Park SK. Environmental cadmium
and lead exposures and age-related macular degeneration in
U.S. adults: the National Health and Nutrition Examination
Survey 2005 to 2008. Environ Res. 2014;133:178e84
367. Wu KH, Tan AG, Rochtchina E, et al. Circulating
inflammatory markers and hemostatic factors in age-related
maculopathy: a population-based case-control study. Invest
Ophthalmol Vis Sci. 2007;48(5):1983e8
368. Wu J, Uchino M, Sastry SM, Schaumberg DA. Age-related
macular degeneration and the incidence of cardiovascular
disease: a systematic review and meta-analysis. PLoS One.
2014;9(3):e89600
369. Wysokinski D, Danisz K, Blasiak J, et al. An association of
transferrin gene polymorphism and serum transferrin levels
with age-related macular degeneration. Exp Eye Res.
2013;106:14e23
370. Xu XR, Zhong L, Huang BL, et al. Comparative
proteomic analysis of plasma proteins in patients
with age-related macular degeneration. Int J Ophthalmol.
2014;7(2):256e63
371. Yang K, Wang FH, Liang YB, et al. Associations between
cardiovascular risk factors and early age-related macular
degeneration in a rural Chinese adult population. Retina.
2014;34(8):1539e53
372. Yao J, Liu X, Yang Q, et al. Proteomic analysis of the aqueous
humor in patients with wet age-related macular
degeneration. Proteomics Clin Appl. 2013;7(7-8):550e60
373. Yating Q, Yuan Y, Wei Z, et al. Oxidized LDL induces
apoptosis of human retinal pigment epithelium through
activation of ERK-Bax/Bcl-2 signaling pathways. Curr Eye
Res. 2014;40:1e8
374. Yildirim O, Ates NA, Tamer L, et al. Changes in antioxidant
enzyme activity and malondialdehyde level in patients with
age-related macular degeneration. Ophthalmologica.
2004;218(3):202e6
375. Yildirim Z, Ucgun NI, Yildirim F. The role of oxidative stress
and antioxidants in the pathogenesis of age-related macular
degeneration. Clinics (Sao Paulo). 2011;66(5):743e6
376. Yip JL, Khawaja AP, Chan MP, et al. Cross sectional and
longitudinal associations between cardiovascular risk
factors and age related macular degeneration in the epicnorfolk eye study. PLoS One. 2015;10(7):e0132565
377. You QS, Xu L, Yang H, et al. Five-year incidence of agerelated macular degeneration: the Beijing Eye Study.
Ophthalmology. 2012;119(12):2519e25
378. Yu Y, Triebwasser MP, Wong EK, et al. Whole-exome
sequencing identifies rare, functional CFH variants in
families with macular degeneration. Hum Mol Genet.
2014;23(19):5283e93
s u r v e y o f o p h t h a l m o l o g y 6 3 ( 2 0 1 8 ) 9 e3 9
379. Zafrilla P, Losada M, Perez A, et al.
Biomarkers of oxidative stress in patients with wet age
related macular degeneration. J Nutr Health Aging.
2013;17(3):219e22
380. Zehetner C, Kirchmair R, Neururer SB, et al. Systemic
upregulation of PDGF-B in patients with neovascular AMD.
Invest Ophthalmol Vis Sci. 2014;55(1):337e44
381. Zeng R, Wen F, Zhang X, Su Y. Serum levels of matrix
metalloproteinase 2 and matrix metalloproteinase 9
elevated in polypoidal choroidal vasculopathy but
not in age-related macular degeneration. Mol Vis.
2013;19:729e36
382. Zhang R, Gascon R, Miller RG, et al. MCP-1 chemokine
receptor CCR2 is decreased on circulating monocytes in
39
sporadic amyotrophic lateral sclerosis (sALS).
J Neuroimmunol. 2006;179(1-2):87e93
383. Zhao M, Bai Y, Xie W, et al. Interleukin-1beta Level Is
Increased in Vitreous of Patients with Neovascular AgeRelated Macular Degeneration (nAMD) and Polypoidal
Choroidal Vasculopathy (PCV). PLoS One.
2015;10(5):e0125150
384. Zhou H, Zhao X, Johnson EJ, et al. Serum carotenoids and
risk of age-related macular degeneration in a chinese
population sample. Invest Ophthalmol Vis Sci.
2011;52(7):4338e44
385. Zolg JW, Langen H. How industry is approaching the search
for new diagnostic markers and biomarkers. Mol Cell
Proteomics. 2004;3(4):345e54